СПОСОБ ПОДАВЛЕНИЯ ПАТОГЕННЫХ И УСЛОВНО-ПАТОГЕННЫХ МИКРООРГАНИЗМОВ

Изобретение относится к медицине, а именно к физиотерапии. Способ включает обработку области, содержащей микроорганизмы, композицией фотосенсибилизатора и фотокатализатора. После этого их выдерживают в течение времени, необходимого для эффективного связывания композиции с клетками микроорганизмов. Затем на указанную область воздействуют оптическим излучением с длинами волн, соответствующими максимуму поглощения фотосенсибилизатора и фотокатализатора, и плотностью мощности, необходимой для активации композиции. При этом в качестве фотосенсибилизатора используют индоцианин зеленый. В качестве фотокатализатора используют наночастицы диоксида титана. Способ повышает эффективность инактивации патогенных и условно-патогенных микроорганизмов за счет повышения чувствительности микроорганизмов к излучению. 7 з.п. ф-лы, 5 ил.

ЧАСТИЦЫ КАДОТРИЛА

Verfahren zur Herstellung haltbarer, viscoser, saurer Rhodanidloesungen

DIE VERWENDUNG VON LACTOPEROXIDASE, EINEM PEROXIDDONOR UND THIOCYANAT ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG EINER INFEKTION MIT HELICOBACTER PYLORI

Solid composition for producing antibacterial, antiviral, antifungal and disinfectant solutions

A solid composition comprising: (a) an immobilized or non-immobilized peroxidase enzymatic catalysing agent; (b) an oxidizable substrate selected from: (i) negatively charged halogens and their derivatives, or (ii) pseudohalogens and their derivatives; (c) at least one oxidising agent, and (d) optionally, at least one inert filler. Also disclosed are kits for preparing such solutions, an aqueous system comprising the composition defined above, a method of sterilising water using said composition and method of preparing an antibacterial solution, disinfectant, antifungal solution or antiviral solution using the composition defined above.

MUTILIN DERIVATIVES

... 1312148 Mutilin derivatives BIOCHEMIE GmbH 10 July 1970 [25 July 1969] 33504/70 Heading C2A Novel mutilin derivatives having the Formula (I) wherein either (i) Y is vinyl, Z is hydrogen and X is -CO-COOH, -CO-CH 2 -R 1 in which R 1 is hydrogen, C 1 -C 4 alkyl, -S-(C 1 -C 5 ) alkyl, -S-(C 1 -C 5 ) alkyl substituted by one or more -NH 2 , -OH or -COOH groups, -S-benzyl, -S-phenyl, -S-phenyl substituted by -COOH or one or two -OH groups, -S-pyridyl, (N,N - tetramethylene - thiocarbamoyl)-mercapto, dithiocarbonic acid-O- (C 1 -C 5 ) alkyl, thiocyanato, azido, chloro, bromo or iodo; or (ii) Y is ethyl, Z is hydrogen and X is -CO-CH 2 -NH 2 or or (iii) Y is hydrogen, Z is acetyl and X is hydrogen, are prepared by (a) reacting the novel compound mutilin 14-tosyloxyacetate of Formula (II) with a compound MeR 1 in which Me is alkali metal and R 1 is as above to give a compound Ia wherein Y is vinyl, Z is hydrogen and X is -CO-CH 2 -R 1 in which R 1 is as above; (b) oxidizing pleuromutilin to give ...

Pharmaceutical compositions containing allyl isothiocyanate

Topical pharmaceutical compositions having rubefacient activity comprise allyl isothiocyanate ("mustard oil") and a vegetable oil.

Pharmaceutical preparations with anthelmintic action.

Method of preparation of diisothiocyanates aromatic.

Process for the preparation of anthelmintic composition.

USE FROM ISOTHIOCYANAT CONNECTIONS TO THE TREATMENT OF PROSTATA ILLNESSES AND SKIN CANCER

TROPOLON DERIVATIVES AS ANTI- MYCOPLASMAMITTEL.

2,2-DIHALOGENO-3,3-DIMETHYLCYCLOPROPAN-DERIVATE

PYRROLIDIN DERIVATIVES SOME PHOSPHOLIPASE-A2 RESTRAINING EFFECT CREDIT

Procedure for the production of new Thiosemicarbazidverbindungen and their salts

USES AND COMPOSITIONS OF NITRATE STAR AS SEDATIVA

Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor

Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Method for treating protozoal infections

Methods for promoting neuronal development and/or health

The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising a neurologic component, wherein the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include lactoferrin, zine sulfate, one or more organosulfur compound, and mixtures thereof.

Sulforaphane for treating or reducing insulin resistance of the liver

The present invention provides sulforaphane, or a plant extract comprising sulforaphane, for treating or reducing insulin resistance of the liver. Especially, there is provided sulforaphane, or a plant extract comprising sulforaphane, for treating or reducing insulin resistance of the liver, wherein, in the subject to be treated, the insulin resistance index of the liver is higher than the insulin resistance of other metabolic tissue.

Sulforaphane-derived compounds, production method thereof and the medical, food and cosmetic use of same

The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins.

Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition

Compositions comprising LSF compositions and treatment regiments comprising administration of LSF containing compositions are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and antioxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided.

Method of synthesising sulforaphane

The present invention relates to a method of synthesising sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesising a stabilised complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent.

Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a broccoli extract or powder and a phytosterol and/or phytostanol or ester thereof. The invention provides compositions and methods relating to these combinations.

TREATMENT OF PRURITIS WITH ESTERS AND AMIDES

Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection

Methods and compositions for mitigating pain

Use of compounds for the elevation of pyruvate dehydrogenase activity

NITRO ALIPHATIC COMPOUNDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF

2-AMINO-SUBSTITUTED ISOTHIOUREIDOBENZENE

... 2-Amino-substituted-isothioureidobenzene products useful as anthelmintics and fungicides are disclosed. The products are prepared by treating 2-amino-thioureidobenzene with a base and an organic halide or sulfonate.

CANCER PREVENTING AND TREATING MEDICINE

... 2,3,4,5,6-penta-o-acetyl-D-gluconyl isothiocyanate is used as prophylactic and therapeutic agent for cancer in a composition comprising a therapeutic amount of the 2,3,4,5,6penta-o-acetyl-D-gluconyl isothiocyanate and a pharmaceutically acceptable diluent or carrier.

PLEUROMUTILIN DERIVATIVES

2-AMINO-SUBSTITUTED ISOTHIOUREIDOBENZENE

ANTIFIBRINOLYTIC AGENTS

COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): FORMULA (I). The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

METHODS FOR TREATING CYSTIC FIBROSIS AND OTHER DISEASES AFFECTING MUCOSAL SURFACES

A method of treating and/or managing cystic fibrosis (CF) and/or other infectious or inflammatory lung disease or mucosal surface condition in a patient in need thereof, using a drug formulation with beneficial and/or synergistic effects among ingredients which comprise the formulation herein reported. Cystic fibrosis disease is characterized by loss of homeostatic balance at mucosal surfaces, resulting in persistent infection, excessive sticky mucus and tissue-destructive host inflammatory responses. When used to treat lung disease, this invention is delivered to airways as an inhaled dose by nebulizer. The formulation(s) arising from this invention are preferably composed of natural endogenous compounds already found within the body but possibly obtained from other sources, and/or of plant phytochemicals, which in combinations herein disclosed, have synergistic hydrating, anti-inflammatory and antimicrobial properties as well as direct corrector and/or potentiator effects and/or other ...

METHOD FOR DETERMINING PHYSIOLOGICAL EFFECTS OF HEMOGLOBIN

NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a cooperative manner, nitrosylates hemoglobin thiols, or reacts with liberated superoxide in solution. The distribution of minor forms of hemoglobin can be tested and the results can be used to predict whether a composition of hemoglobin will scavenge, load, eliminate, or donate NO. Hemoglobin thus serves to regulate the chemistry of NO. SNO-hemoglobin transfers NO equivalents to the red blood cell anion transport protein AE1, which serves to export NO from red blood cells. Regulation of AE1 function is the basis for methods of therapy to affect levels of NO or its biological equivalent.

METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES

The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of nerounal cell death in the centeral nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

PHOSPHATE BINDING MATERIALS AND THEIR USES

Phosphate binding materials and compositions comprising them which are solid ligand-modif ied poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo- hydroxides modified with carboxylic acid ligands, or ionised forms thereof. These materials are made and tested in the examples provided in the application to demonstrate that they can bind phosphate in "in vitro" an in "in vivo" studies. They are useful for treating hyperphosphatenia or for removing phosphate from a medium.

METHOD OF SYNTHESISING SULFORAPHANE

The present invention relates to a method of synthesising sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesising a stabilised complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent.

TREATMENT FOR ATHEROSCLEROSIS AND OTHER CARDIOVASCULAR AND INFLAMMATORY DISEASES

Dithiocarboxylates, including dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM1, and are therefore useful in the treatment of cardiovascular disease, including atherosclerosis, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.

COMPOSITIONS BASED ON PLANT EXTRACTS

Composition comprenant au moins un hétéropolysaccharide du type pectine et un composé choisi dans le groupe consistant en caroténoïdes, notamment lycopène, et glucosinolate et/ou sulphoraphane et mélanges de ceux-ci. Applications médicales, diététiques et cosmétiques, notamment grâce à leurs propriétés curatives et préventives vis-à-vis des métaux lourds, anti-oxydante, antiradicalaire et leur action favorable sur la régénération cellulaire.

Verfahren zur Herstellung von aromatischen Diisothiocyanaten

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Verfahren zur Herstellung neuer Isothiocyanato-diphenylamine

Procédé de préparation de nouveaux diisothiocyanates

Procédé de préparation de nouveaux diisothiocyanates

Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen

Verfahren zur Herstellung von Thiosemicarbazidverbindungen

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Active principle of anthelmintic preparations comprises - isothiocyanodiphenylamines

Active principle of anthelmintic preparations comprises isothiocyanodiphenylamines. G3A. Cpds. of formula: (in which R is hydrogen, alkyl or alkylene, with at most 3 C atoms, R1 and R3 independently of each other are hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, trifluoromethyl, alkyl, alkenyl, alkoxy, alkenyloxy, alkylathio, alkenylthio with a max. of 5C atoms, alkanoylamino, alkanoyl, alkanoyloxy, alkylthio, with a max. of 5C atoms in the alkyl. in which D is alkylene with 2 or 3 C atoms, R1 is alkylene with 1 to 3 C atoms and X is oxygen or S and R2 is hydrogen, halogen, nitro, isothiocyano or alkyl with a max. of 5C atoms, with the proviso that there is no isothiocyano ortho to hydroxy, carboxy or, when R is H, to the -NH- bridge and in the A and B benzene nuclei both para positions to an -NH- bridge can be occupied by isothiocyano groups only in the cases where R1 and/or R3 are substituents different from H, are prepared by reacting 41-aminodiphenylamines with cpds. such as ...

Verfahren zur Herstellung neuer Isothiocyanato-N-alkanoyl-diphenylamine

Substd phenylacetic acid cpds - with anti-inflammatory analgesic and anti-pyretic activity

Substd. phenylacetic acids have the formula (I): (where R1 is 5-7C cycloalkyl, lower alkyl substd. cycloalkyl, 1-8C alkyl, phenyl, opt. substd. by trifluoromethyl, hal, lower alkylsulphonyl, nitro or cyano; R2 is hal, nitro, cyano, trifluoromethyl, lower alkyl sulphonyl, and when R1 is a substd. phenyl, R2 is H; R3 is H, and R1 is a substnt. other than cyclohexyl, R3 is lower alkyl; X is hal, mercapto, lower alkylthio, lower alkylsulphonyl, thiocyano, cyano, -SO3M (M is substantially nontoxic alkali metal), -S2O3M, lower alkanoylthio, lower alkylxanthyl, isothioureido, amino, mono- and di-(lower alkyl)amino, lower alkanoylamino, substnt. having the formula: where Z is bond or S; Y is hydroxy, amino -N-R" (R' and R" are H, lower alkyl, and aralkyl, or R' and R" form a hetero ring with the N to which they are attached); and X and Y may form a hetero ring of formula:-.

Process for the preparation of isothioureidobenzenes

НОВЫЕ ПРОИЗВОДНЫЕ ПЕНТАЭРИТРИТА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ , А ТАКЖЕ ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ СИНТЕЗА

Изобретение описывает новые производные пентаэритрита общих формул I, XIV, XVI, XIX и XXII, заместители которых имеют значения, указанные в описании, и могут быть использованы в качестве фармацевтически активных веществ, в частности, для лечения заболеваний сердца/органов кровообращения.

PHARMACEUTICAL COMPOSITION, POSSESSING ANTIMICROBIAL, BACTERIOSTATIC EFFECT (VERSIONS)

FARMATsEVTIChESKIEKOMPOZITsII, that GLITAZONY AND Nrf2 AKTIVATORYSODERZhAT

НОВЫЕ ПРОИЗВОДНЫЕ ПЕНТАЭРИТРИТА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ, А ТАКЖЕ ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ СИНТЕЗА

Изобретение описывает новые производные пентаэритрита общих формул I, XIV, XVI, XIX и XXII, заместители которых имеют значения, указанные в описании, и могут быть использованы в качестве фармацевтически активных веществ, в частности, для лечения заболеваний сердца/органов кровообращения. Международная заявка была опубликована вместе с отчетом о международном поиске.

Fe(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS

Traditional Chinese medicine extract and preparation method thereof

The invention relates to a natural pharmaceutical composition and a preparation method thereof, and application of the natural pharmaceutical composition in preparation of attenuated synergistic medicines in cancer chemotherapy. The natural pharmaceutical composition is composed of radix astragali/radish seed water-decocted concentrated extract, radix astragali polysaccharide and raphanin in a ratio of (6-8):(3-4):(5-8). The composition has excellent curative effects on diarrhoea related to cancer chemotherapy, and meanwhile, has a synergistic action on cancer chemotherapy.

Pharmaceutical compositions for the treatment of acne

Disclosed is a pharmaceutical composition for treating acne, which comprises rhubarb horsetails, clove, root of red rooted saliva, citron fruit, red halloysite, baras camphor and momordica seed. The composition has the advantages of low cost, short course of treatment, higher curing rate and low recurrence rate.

Regulation of cancer using natural/compounds and/or diets

NOVEL DERIVATIVES OF PHENYL (SUBSTITUTED) [...] ACIDS

NOVEL DERIVATIVES OF PHENYL (SUBSTITUTED) [...] ACIDS

Conversion of isothiocyanodiphenylamines to the - corresponding n-nitroso cpds

NEW ISOTHIOCYANO-DIPHENYLAMINES THEIR PRODUCTION AND COMPOSITIONS CONTAINING SAME

New derivatives of naphtamides, their method of preparation and their application in the domainethérapeutique one

Ces nouveaux dérivés répondent à la formule générale: (CF DESSIN DANS BOPI) où X représente un atome d'hydrogène, un atome d'halogène tel que le chlore ou le brome, un groupe amino ou amino-alkyle, un groupe amino-méthylsulfonyle ou amino-sulfamoyle, un groupe alcoxy inférieur tel qu'un groupe méthoxy, un groupe nitro ou encore un groupe cyano, R représente un groupe alkyle inférieur, un groupe cycloalkyle-alkyle inférieur, un groupe aralkyle tel qu'un groupe phénylalkyle ou encore le groupe allyle. Ces nouveaux dérivés peuvent servir à la préparation de médicaments destinés à être utilisés comme agent antipsychotique, psychostimulant, antiautistique, antidépresseur, antiparkinsonien ou antihypertenseur.

NEW DERIVATIVES OF NAPHTAMIDES, THEIR METHOD OF PREPARATION AND THEIR APPLICATION IN THE THERAPEUTIC FIELD.

NEW DERIVATIVES OF NAPHTAMIDES, THEIR METHOD OF PREPARATION AND THEIR APPLICATION IN THE THERAPEUTIC FIELD.

PHOSPHATE BINDING MATERIALS AND THEIR USES

N-ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE (NAAA) INHIBITORS AND USE THEREOF

Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhibit) N- acylethanolamine hydrolyzing acid amidase (NAAA) and thereby treat a variety of diseases, disorders and conditions mediated by NAAA, such as a gastrointestinal motility disorder, irritable bowel syndrome, an inflammatory bowel disorder, neuroinflammation, nicotine addiction, cancer, opioid dependence, analgesia, chemotherapy-induced neuropathic pain and pain. Also disclosed herein are compositions and methods including compounds of Structural Formula I, or a pharmaceutically acceptable salt thereof ...

ANTIPRURITIC

The purpose of the invention is to provide an antipruritic that exerts an antipruritic effect immediately against refractory pruritus typified by atopic dermatitis. The invention provides an antipruritic containing sulforaphane or a precursor thereof as an active ingredient.

FOOD INTAKE, BODY WEIGHT AND GLUCOSE METABOLISM REGULATION BY MODULATION OF P2Y6 RECEPTOR SIGNALING

The present invention is related to compound capable of regulating the activity of P2Y purinoceptor 6 signaling pathway, especially to compounds for inhibition of P2Y purinoceptor 6 polypeptide or inactivation, degradation, downregulation or intercalation of a nucleic acid encoding P2Y purinoceptor 6 or downregulation of P2Y purinoceptor 6 signaling pathway for the treatment of diseases related to energy balance as well as carbohydrate metabolism and homeostasis, preferably glucose metabolism and homeostasis. The present is also related to compounds for activation of P2Y purinoceptor 6 polypeptide or upregulation or modification for advanced transcriptional activity of a nucleic acid encoding P2Y purinoceptor 6, upregulation of P2Y purinoceptor 6 signaling pathway for gaining weight or for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of identifying said compounds suitable for the treatment of ...

NEW USE

The present invention provides the use of a low molecular weight mammalian AP endonuclease inhibitor for the preparation of a medicament for the treatment of cancer.

NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS

A first aspect of the invention is a compound (sometimes also referred to herein as an "active agent" or "active compound") of Formula (I) or ( Ia): or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.

PREVENTION AND TREATMENT OF DEGENERATIVE DISEASES BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES

The present invention generally relates to the field of treating degenerative disease by administering a pharmaceutically effective amount of a compound that elevates glutathione or at least one Phase II detoxification enzyme in diseased tissue. The present invention also relates to a pharmaceutical composition useful for the treatment of degenerative diseases, as well as a method of identifying agents that modulate intracellular levels of glutathione or intracellular levels of at least one Phase II enzyme in neuronal cells.

ALLYL ISOTHIOCYANATE AND USE THEREOF TO INHIBIT HAIR LOSS

Allyl isothiocyanate is useful to inhibit human hair loss.

CURING ACCELERATOR AND METHOD OF MAKING

A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein the sterilized cyanoacrylate adhesive composition does not cure upon sterilization. A kit for applying the sterilized cyanoacrylate adhesive composition, including the cyanoacrylate adhesive composition and an applicator. A method of making the sterilized cyanoacrylate adhesive composition, by adding a cure speed enhancer to a cyanoacrylate adhesive composition and sterilizing the composition. A method of applying the sterilized cyanoacrylate adhesive composition to tissue by applying the sterilized cyanoacrylate adhesive composition as a liquid, and quickly curing the sterilized cyanoacrylate adhesive composition. A method of sealing tissue by applying the sterilized cyanoacrylate adhesive composition as a liquid to tissue to be sealed, quickly curing the sterilized cyanoacrylate adhesive composition, and sealing the tissue.

Methods and composition for the treatment of cystic fibrosis and related illnesses

The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are functionally redundant to the cystic fibrosis transmembrane conductance regulator (CFTR), allowing for the substrate conjugates to be exported from the cell. The export of GSH conjugates restores intracellular and extracellular levels of GSH to normal levels. Normalizing both extracellular and intracellular GSH via the increased conjugation of isothiocyanates with GSH, and subsequent export, can significantly rectify numerous enzymatic processes and correct the pathologies that are typical of patients suffering from cystic fibrosis.

Isoprenylic acid amide derivatives

Compounds of the formula R1 --CO--NH2 wherein R1 is см. иллюстрацию в PDF-документе are described. The compounds are useful in the treatment of hypertension and hyperlipidemia.

Sickle cell anemia control

Method of providing anti-sickling of red blood cells in sickle cell anemia patients without hemolyzing said cells, using thiocyanates alone, or together with Vitamin B6.

Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs, and Organisms

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

COMBINATION THERAPY COMPRISING PLANT DERIVED COMPOUNDS AND ANTINEOPLASTIC COMPOUNDS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES

INHIBITOR FOR MASTOCARCINOMA AND MELANOCARCINOMA

PROBLEM TO BE SOLVED: To obtain an inhibitor for mastocarcinoma and melanocarcinoma, having specifically excellent inhibitory action for the mastocarcinoma and melanocarcinoma. SOLUTION: This inhibitor for the mastocarcinoma and melanocarcinoma includes 6-methylsulfinylhexylisothianate as the effective ingredient. COPYRIGHT: (C)2001,JPO ...

ANTIFIBRINOLYTIC AGENTS

... 1518330 Antifibrinolytic compositions containing aminoalkane sulphonic acids STANLEY DRUG PRODUCTS INC 8 Aug 1975 [8 Aug 1974] 33174/75 Heading A5B [Also in Division C2] Compositions effective in the control of hyperplasminaemia comprise an omega-aminoalkanesulphonic acid having the formula where n equals 1, 2, 3 or 4 or a non toxic salt or adduct thereof in admixture with a pharmaceutically acceptable carrier or diluent, the composition being in an injectable or orally administrable form.

(THIO) CARBAMIDINSÄURE DERIVATIVES AND THESE CONTAINING DRUGS

PROCEDURE FOR THE PRODUCTION OF DIAMINOTHIOCYANATO BENZENE DERIVATIVES AS WELL AS OF THEIR SALTS

SPHERICAL SINGLE CRYSTALS FUER PHARMACEUTICAL PURPOSES.

THE USE OF LACTOPEROXIDASE, A PEROXIDDONOR AND THIOCYANAT FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF AN INFECTION WITH HELICOBACTER PYLORI

Procedure for the production of new Diisothiocyanaten

Anti-inflammatory activity of phenethylisothiocyanate (PEITC) and the Barbarea verna seed preparation containing this compound

Compositions and methods for human gastrointestinal health

METHODS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION

Compositions and methods for human gastrointestinal health

Novel Method For Delivery and Use of Isothiocyanates For Prophylaxis and/or Therapy of Bladder Cancer

Provided is a composition that contains a mixture of broccoli seed and mustard seed. Before mixing the broccoli seed with the mustard seed, the broccoli seed is subjected to baking and a pressurized heat treatment. The broccoli seed is baked at a temperature of at least 200 degrees Fahrenheit for at least 60 minutes, and is subjected to a pressurized heat treatment of at least 200 degrees Fahrenheit at a pressure of at least 10 pounds/square inch for at least 5 minutes. Also provided is a method for therapy and/or prophylaxis of bladder cancer in an individual. The method entails administering orally to the individual a composition that contains an isothiocyanate (ITC) or a derivative thereof such that the administration inhibits the growth and/or recurrence of bladder cancer. Nutraceutical compositions are also provided. 1. A composition comprising a mixture of broccoli seed and mustard seed , wherein the broccoli seed has been subjected to baking and a pressurized heat treatment before being mixed with the mustard seed.2. The composition of claim 1 , wherein the broccoli seed was baked at a temperature of at least 200 degrees Fahrenheit for at least 60 minutes before being mixed with the mustard seed.3. The composition of claim 2 , wherein the pressurized heat treatment comprises a pressurized steam treatment at a temperature of at least 200 degrees Fahrenheit at a pressure of at least 10 pounds/square inch (p.s.i.) for at least 5 minutes.4. The composition of claim 1 , wherein the broccoli seed comprises at least 90 micromoles/gram glucoraphanin.5. The composition of claim 4 , wherein the broccoli seed comprises heat inactivated epithiospecifier protein (ESP).6. The composition of claim 5 , wherein the mustard seed comprises at least 90 micromoles/gram sinigrin.7. The composition of claim 5 , wherein the mixture of the broccoli seed and the mustard seed is powdered.8. A method for therapy and/or prophylaxis of bladder cancer in an individual comprising ...

METHODS AND COMPOSITIONS FOR TREATMENT OF AUTISM

Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder. 1. A method of treating autism or one or more autism spectrum disorders , comprising ,administering to a subject diagnosed with autism or one or more autism spectrum disorders an effective amount of a composition comprising a compound that induces a general cellular stress response in at least one cell of the subject; andallowing the cells of the subject to return to homeostasis substantially equivalent to the state that existed in the cells prior to administering the compound.2. The method of claim 1 , wherein in at least one cell of the subject claim 1 , the stress proteome is stimulated.3. The method of claim 1 , wherein in at least one cell of the subject claim 1 , increased nitrous oxide production is measured.4. The method of claim 1 , wherein in at least one cell of the subject stress-sensing organelles are increased from an amount prior to the administration of the composition.5. The method of claim 4 , wherein a stress-sensing organelle is a mitrochondrion.6. The method of claim 4 , wherein a stress-sensing organelle is a peroxisome.7. The method of claim 1 , wherein a general cellular stress response comprises at least one of mitochondrial biogenesis claim 1 , peroxisome proliferation claim 1 , activation of the stress proteome claim 1 , transcription and/or translation of genes and proteins encoded by genes comprising heat shock and unfolded protein claim 1 , genes for autophagic responses claim 1 , genes for antioxidant responses claim 1 , and genes for the c-jun-N-terminal kinase pathway.8. The method of claim 7 , wherein genes for heat shock proteins comprise heat shock protein 40 claim 7 , 70 claim 7 , and/or 90 family members; unfolded protein genes comprise glucose regulated protein 78 (BIP) claim 7 , PERK claim 7 , inositol requiring 1 (IRE1) and activating transcription factor 6; autophagic ...

Adamantyl Derivatives as Therapeutic Agents

The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis. 2. The compound of claim 1 , wherein Ris unsubstituted or substituted C-Calkyl and Rand Rare each hydrogen.3. The compound of claim 2 , wherein Xis S and Xis 0.4. The compound of claim 3 , wherein m and n are each 1 and p is 0.5. The compound of claim 4 , wherein Ris —C(O)OR.6. The compound of claim 1 , wherein R claim 1 , Rand Rare each claim 1 , independently claim 1 , hydrogen claim 1 , nitro claim 1 , unsubstituted or substituted C-Calkyl claim 1 , unsubstituted or substituted C-Caryl claim 1 , unsubstituted or substituted heteroaryl comprising 1-4 heteroatoms selected from N claim 1 , O and S claim 1 , unsubstituted or substituted C-Calkenyl claim 1 , unsubstituted or substituted Calkynyl claim 1 , hydroxyl claim 1 , halogen claim 1 , or —NRR.7. The compound of claim 1 , wherein m claim 1 , n and p are each claim 1 , independently claim 1 , integers from 0 to 10.10. The compound of claim 9 , wherein Rand R are each claim 9 , independently claim 9 , a bond or unsubstituted or substituted C-Calkyl.11. The compound of claim 10 , wherein both (AA)and (AA) claim 10 , comprise one or more α-amino acids.12. The compound of claim 11 , wherein q and r are each claim 11 , independently claim 11 , integers from 1 to 10.13. The compound of claim 12 , wherein q and r are each claim 12 , independently claim 12 , integers from 1 to 5.14. A method for treating cancer in a subject in need of such treatment claim 1 , the method comprising administering to said subject a therapeutically effective amount of a compound of .15. The method of claim 14 , wherein the cancer is selected from the group consisting of: neuroblastoma claim 14 , ovarian cancer claim 14 , breast cancer claim 14 , cervical cancer claim 14 , endometrial cancer claim 14 , prostate cancer claim 14 , pancreatic cancer ...

Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes

The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. 1. A method of treating a subject in need of treatment of an oxidative stress disorder , said method comprising administering to said subject a composition comprising a pharmaceutically effective amount of a compound that elevates intracellular levels of glutathione or intracelluar levels of at least one Phase IT detoxification enzyme in diseased tissue of said subject , wherein said oxidative stress disorder is selected from the group consisting of Alzheimer's Disease and aging.2. The method of claim 1 , wherein said compound is selected from the group consisting of an isothiocyanate and a glucosinolate.3. The method of claim 2 , wherein said isothiocyante is sulforaphane.4. (canceled)5. The method of claim 1 , wherein said Phase IT detoxification enzyme is selected from the group consisting of UDP-glucuronosyltransferases claim 1 , sulfotransferases claim 1 , phenol-O-methyltransferase claim 1 , catechol-O-methyltransferase claim 1 , histamine N-methyltransferase claim 1 , nicotinamide N-methyltransferase claim 1 , thiopurine methyltransferase claim 1 , thiol methyltransferase claim 1 , N-acetyltransferases claim 1 , O-acetyltransferases claim 1 , acyl-CoA synthetases claim 1 , acyl-CoA:amino acid N-acyltransferases claim 1 , aminoacyl-tRNA ...

Compositions and Methods for Depleting Mutant p53

The invention is directed towards methods of treating abnormal tissues in a subject or sensitizing an abnormal tissue to a chemotherapeutic agent. The methods comprise screening at least a portion of an abnormal tissue for at least one mutant form of p53 protein, and administering at least one isothiocyanate (ITC) to the subject or abnormal tissue if the abnormal tissue is positive for the at least one mutant form of p53. 1. A method of treating an abnormal tissue in a subject , the method comprisinga) screening at least a portion of the abnormal tissue for at least one mutant form of p53 protein, andb) administering at least one isothiocyanate (ITC) to the subject if the abnormal tissue is positive for the at least one mutant form of p53.2. The method of claim 1 , wherein the subject is a mammal.3. The method of claim 1 , wherein the abnormal tissue is cancerous.4. The method of claim 1 , wherein the ITC is sulforophane (SFN) claim 1 , phenylethyl ITC (PEITC) claim 1 , benzyl ITC (BITC).5. The method of claim 1 , wherein the ITC is conjugated.6. The method of claim 5 , wherein the conjugate to the ITC is a thiol conjugate.7. The method of claim 1 , wherein the abnormal tissue is lung tissue claim 1 , breast tissue claim 1 , colon tissue and prostate tissue.8. The method of claim 1 , wherein ITC is administered orally.9. The method of claim 1 , further comprising co-administering an anti-cancer agent with the ITC.10. The method of claim 1 , wherein the mutant p53 has a mutation at V143 claim 1 , P151 claim 1 , R175 claim 1 , G245 claim 1 , R248 claim 1 , R249 claim 1 , R273 claim 1 , P274 claim 1 , R280 and R282 of the amino acid sequence of SEQ ID NO:1.11. A method of altering the three-dimensional conformation of a mutant p53 protein claim 1 , the method comprising administering at least one isothiocyanate (ITC) to the mutant p53 protein to alter the three-dimensional conformation of the mutant p53 protein.12. The method of claim 11 , wherein the mutant p53 ...

PREVENTION OF PROTEOMIC AND GENOMIC DAMAGE BY DICARBONYL SUBSTRATES OF GLO 1

The invention concerns the role of Glo 1 in the prevention and reversal of proteomic and genomic damage by carbonyl substrates thereof and, in particular, therapeutics that promote Glo 1 production. 122-. (canceled)23. A screening method for identifying agents that prevent and/or reverse proteomic and/or genomic damage , by dicarbonyl substrates of Glo1 , by inducing the increased expression of the GLO1 gene comprising:a) providing a cell including the GLO1 gene promoter functionally coupled to the coding region of the GLO1 gene and/or the coding region of a selected reporter gene and associated transcription machinery for producing a Glo1 gene product and/or a reporter gene product;b) exposing said cell to at least one test agent;c) investigating said cell for the production of said GLO1 gene product and/or reporter gene product; andd) where said product is produced, or its amount increased, after exposure to the test agent, concluding said test agent has use in inducing the expression of Glo1 and so preventing proteomic and genomic damage by dicarbonyl substrates of Glo1.24. The method according to wherein said cell is a recombinant cell that has been transformed or transfected with a construct encoding said GLO1 gene.25. The method according to wherein said GLO1 gene comprises at least one antioxidant response element (ARE).26. The method according to wherein said GLO1 gene comprises a plurality of AREs.29. The method according to wherein said GLO1 gene comprises the wild-type promoter.30. The method according to wherein said GLO1 gene comprises an artificial promoter.32. A construct encoding the promoter region of the GLO1 gene or a recombinant version thereof claim 23 , including an artificial promoter comprising a plurality of AREs.33. The construct according to further comprising the encoding region of the GLO1 gene and/or the coding region of a gene encoding a reporter molecule functionally linked to said promoter whereby the production of Glo1 protein and/ ...

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions. 1. A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food , the method comprising providing the patient with a medical food composition comprising a first compound that reduces degradation of dopamine and a second compound that increases synthesis of dopamine.2. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis.3. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying one or more biomarkers indicating a disruption in the prefrontal dopamine axis.4. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a disruption in the patient's catechol methyltransferase pathway(s).5. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a polymorphism in the patient's COMT gene claim 1 , MTHFR gene or both COMT and MTHFR genes leading to a decrease in dopamine.6. The method of claim 1 , wherein providing the first compound that reduces degradation of dopamine comprises phosphatidylserine.7. The method of claim 1 , wherein providing the second compound that increases synthesis of dopamine comprises methylfolate.8. The method ...

NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction

Methods for the treatment or prevention of diseases which are caused by the decreased concentrations of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by the methods of the invention include chronic obstructive pulmonary disease (COPD) and asthma, including steroid resistant COPD and asthma. The invention provides methods for treating or preventing of diseases caused by the degradation of HDAC2 by providing to the subject in need of treatment or prevention a molecular compound capable of preventing the degradation of HDAC2. Such molecular compounds include Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators. Methods are further provided for the treatment and prevention of COPD and asthma by providing to a subject in need of such treatment and prevention a nucleic acid which causes expression of HDAC2 in lung cells and/or a nucleic acid which causes expression of Nrf2 in lung cells. 1. A method for the treatment of an inflammatory disorder in a subject comprising concomitantly administering to the subject a pharmaceutical formulation comprising:an effective amount of a corticosteroid; andan effective amount of a Nrf2 activator.2. The method of claim 1 , wherein the inflammatory disorder is chronic obstructive pulmonary disorder (COPD).3. The method of claim 1 , wherein the inflammatory disorder is selected from the group consisting of: acne vulgaris claim 1 , asthma claim 1 , autoimmune diseases claim 1 , celiac disease claim 1 , chronic prostatitis claim 1 , glomerulonephritis claim 1 , hypersensitivities claim 1 , inflammatory bowel diseases claim 1 , pelvic inflammatory disease claim 1 , reperfusion injury claim 1 , rheumatoid arthritis claim 1 , sarcoidosis claim 1 , transplant rejection claim 1 , vasculitis claim 1 , and interstitial cystitis.4. The method of claim 1 , wherein the Nrf2 activator is sulphoraphane.5. The method of claim 1 , wherein the Nrf2 activator is selected from the group consisting of: tert- ...

Antihypertensive Composition

The present invention relates to a composition having a concentration-promoting and/or stimulating effect, in particular for the simultaneous lowering of arterial blood pressure, wherein said composition contains as component (a) at least one nitrate source and/or nitrate and as component (b) at least one substance having a stimulating and/or stimulating effect, preferably caffeine. 115-. (canceled)16. A composition , comprising:(a) at least one nitrate source; and(b) caffeine;wherein the composition promotes concentration, has a stimulating effect, and/or lowers arterial blood pressure.17. The composition according to claim 16 , wherein the at least one nitrate source contains nitrate in an amount of 1-10 claim 16 ,000 mg claim 16 , based on the total weight of NOand/or NOper serving or application unit of the composition.18. The composition according to claim 16 , wherein the at least one nitrate source is selected from vegetable nitrate sources claim 16 , salts of nitric acid claim 16 , esters of nitric acid and combinations thereof.19Spinacia oleraceaRaphanusBeta vulgarisBrassica rapaDiplotaxis tenuifoliaLepidiumValerianella. The composition according to claim 18 , wherein the at least one nitrate source is a vegetable nitrate source selected from plants of the group of (vegetable spinach) claim 18 , (radish) claim 18 , (common turnip) claim 18 , (turnip) claim 18 , (arugula) claim 18 , (cress) and (lamb's lettuce).20Beta vulgaris. The composition according to claim 18 , wherein the at least one nitrate source is a vegetable nitrate source derived from the yellow claim 18 , red and/or white cultivated form of (common turnip).21. The composition according to claim 18 , wherein the at least one nitrate source is a vegetable nitrate source in the form of liquid plant components or solid plant components.22. The composition according to claim 17 , wherein the at least one nitrate source is a salt of nitric acid selected from alkali metal and alkaline earth metal ...

COMPOSITIONS FOR ANTI-INFLAMMATORY, ANTIOXIDANT EFFECTS AND IMPROVED RESPIRATORY FUNCTION BY SPECIFIC HISTONE DEACETYLASE INHIBITION

Compositions comprising LSF compositions and treatment regiments comprising administration of LSF containing compositions are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided. 1. A pharmaceutical composition for treatment , suppression and/or amelioration of a condition or disease associated with inflammation or oxidative stress , wherein said composition comprises L-sulforaphane (LSF) , an LSF derived and/or substituted compound , and/or an LSF analogue.3. The composition of wherein R is selected from the group consisting of hydrogen claim 1 , substituted or unsubstituted alkyl claim 1 , substituted or unsubstituted alkenyl claim 1 , substituted or unsubstituted alkynyl claim 1 , substituted or unsubstituted aryl claim 1 , substituted or unsubstituted heterocyclyl claim 1 , substituted or unsubstituted acyl claim 1 , ORa claim 1 , SRa claim 1 , SORa claim 1 , SO2Ra claim 1 , OSO2Ra claim 1 , OSO3Ra claim 1 , NO2 claim 1 , NHRa claim 1 , N(Ra)2 claim 1 , ═N—Ra claim 1 , N(Ra)CORa claim 1 , N(CORa)2 claim 1 , N(Ra)SO2R′ claim 1 , N(Ra)C(═NRa)N(Ra)Ra claim 1 , CN claim 1 , halogen claim 1 , CORa claim 1 , COORa claim 1 , OCORa claim 1 , OCOORa claim 1 , OCONHRa claim 1 , OCON(Ra)2 claim 1 , CONHRa claim 1 , CON(Ra)2 claim 1 , CON(Ra)ORa claim 1 , CON(Ra)SO2Ra claim 1 , PO(ORa)2 claim 1 , PO(ORa)Ra claim 1 , PO(ORa)(N(Ra)Ra) and aminoacid ester having inhibitory efficacy against the LSD1 protein; and further wherein each of the Ra groups is independently selected from the group consisting of hydrogen claim 1 , substituted or unsubstituted alkyl claim 1 , ...

PROSTAGLANDIN TRANSPORTER INHIBITORS FOR INHIBITING OVULATION

The present invention provides methods and compositions for inhibiting ovulation in a female subject, including a subject in need of contraceptives and a subject undergoing fertility treatments. The methods comprise administering to the female subject at least one prostaglandin transporter (PGT) inhibitor. 130-. (canceled)31. A method for inhibiting ovulation in a female subject , comprising administering to said female subject a pharmaceutical composition comprising at least one prostaglandin transporter (PGT) inhibitor.32. The method of claim 31 , wherein said PGT inhibitor is capable of inhibiting at least one of oocyte nuclear maturation claim 31 , cumulus expansion or follicular rupture.33. The method of claim 31 , wherein said pharmaceutical composition is administered daily from one to four days prior to a mid-cycle.34. The method of claim 33 , wherein said pharmaceutical composition is administered daily during the mid-cycle and at least one day thereafter.35. The method of claim 31 , wherein said pharmaceutical composition is administered daily from day 9 of a menstrual cycle to day 14 of the menstrual cycle.36. The method of claim 31 , further comprising measuring a luteinizing hormone (LH) level.37. The method of claim 36 , further comprising administering said pharmaceutical composition daily claim 36 , from a day that the LH level surges until claim 36 , and including claim 36 , a day that LH level drops to baseline.38. The method of claim 31 , further comprising measuring estradiol levels.39. The method of claim 38 , further comprising administering said pharmaceutical composition daily claim 38 , at a day that the estradiol level surges and at least four consecutive days thereafter.40. The method of claim 31 , further comprising measuring a level of estradiol and luteinizing hormone (LH) and administering said pharmaceutical composition daily from a day that the level of estradiol surges and until a day that the level of LH drops to baseline.41. The ...

REGULATION OF CANCER USING NATURAL COMPOUNDS AND/OR DIET

The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout. 1. A method of treating a subject for a proliferative disease , comprising:a) administering to the subject in need of such treatment, an effective amount of a composition comprising epigallocatechin-3-gallate, a composition comprising curcumin, and a composition comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and/or sulforaphane (SFN), and, optionally, providing a modified ketogenic diet or a ketogenic diet to the subject; orb) providing a modified ketogenic diet or a ketogenic diet to the subject; and, optionally, administering to the subject in need of such treatment, an effective amount of a composition comprising epigallocatechin-3-gallate, a composition comprising curcumin, and a composition comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and/or sulforaphane (SFN).2. The method of claim 1 , wherein the proliferative disease is a cancer.3. The method of claim 2 , wherein the proliferative disease is a cancer selected from the group consisting of Acute Lymphoblastic Leukemia claim 2 , Acute Myeloid Leukemia claim 2 , Adrenocortical Carcinoma claim 2 , AIDS-Related Cancers claim 2 , AIDS-Related Lymphoma claim 2 , Anal Cancer claim 2 , Appendix Cancer claim 2 , ...

Method for Treating Skin Cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Method for Treating Skin Cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 15-. (canceled)712-. (canceled) This application is a continuation of U.S. application Ser. No. 14/519,510, entitled “METHOD FOR TREATING SKIN CANCER,” filed Oct. 21, 2014, which is a continuation of U.S. application Ser. No. 13/952,236, entitled “METHOD FOR TREATING SKIN CANCER,” filed Jul. 26, 2013, now U.S. Pat. No. 8,865,772, which claims the benefit of U.S. Provisional Application Ser. No. 61/676,093, entitled “METHOD FOR TREATING SKIN CANCER,” filed Jul. 26, 2012 —which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present invention relates in general to a method for treating skin cancer (e.g., skin neoplasms) and, more particularly, to a method for treating a plurality of forms of skin cancer including, but not limited to, basal cell carcinoma, squamous cell carcinoma, and melanoma.2. Background ArtSkin cancer is a general term for many types of skin growths, also known as skin neoplasms. The most common form of skin cancer is basal cell carcinoma. However, there are many other different forms of skin cancer including, squamous cell carcinoma, melanoma, and merkel cell carcinoma—among others.Skin cancer occurs in people of all races and can affect people of any age. Skin cancer is the most commonly diagnosed type of cancer. Ultraviolet radiation from sun exposure is the primary cause of skin cancer, however, other factors can play a role including, smoking tobacco, human papillomavirus infections, genetics, chronic non-healing wounds, environmental carcinogens, artificial ultraviolet radiation, aging, and light skin color—just to name ...

Method for Treating Eczema

A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION

This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided.

Method for Treating Eczema

A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 14-. (canceled)5. A method for treating eczema , comprising the step(s) of:applying a lysine derivative to an area affected by eczema, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.610-. (canceled)11. The method for treating eczema claim 5 , according to claim 5 , further comprising the step of applying an additional surfactant claim 5 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 5 , an anionic surfactant claim 5 , a cationic surfactant claim 5 , a zwitterionic surfactant claim 5 , and combinations thereof.12. The method for treating eczema claim 5 , according to claim 5 , wherein the eczema is selected from one of the groups comprising atopic eczema claim 5 , contact eczema claim 5 , allergic contact eczema claim 5 , seborrheic eczema claim 5 , nummular eczema claim 5 , neurodermatitis claim 5 , stasis dermatitis claim 5 , and/or dyshidrotic eczema. This application is a continuation of U.S. application Ser. No. 14/519,462, entitled “METHOD FOR TREATING ECZEMA,” filed Oct. 21, 2014, which is a continuation of U.S. application Ser. No. 13/348,821, entitled “METHOD FOR TREATING ECZEMA,” filed Jan. 12, 2012, now U.S. Pat. No. 8,865,765, which claims the benefit of U.S. Provisional Application Ser. No. 61/431,977, entitled “METHOD FOR TREATING ECZEMA,” filed Jan. 12, 2011 and U.S. Provisional Application Ser. No ...

COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE

In addition to its potent mechanism-dependent inhibition of estrogen biosynthesis, in accordance with the embodiments of the present invention, it has now been found that exemestane has novel chemoprotective properties which have hitherto not been explicitly recognized. The present invention provides methods for the use of compositions comprising exemestane for chemoprotection against a wide variety of non-mammary tumors (and possibly other chronic diseases) that are not estrogen-dependent, but have oxidative stress, inflammation and electrophile-damaging etiologies. The present invention also shows that exemestane shows powerful synergism with other classes of Nrf2-activators and phase 2 enzyme gene activators, including, for example sulforaphane (an isothiocyanate), shikonin (a naphthoquinone), zerumbone (a cyclic sesquiterpene) and resveratrol (a stilbene derivative), which increases the attractiveness of exemestane's novel uses. 1. A composition comprising an effective amount of exemestane and/or a derivative thereof and/or an effective amount of exemestane and/or analogue or derivative thereof and an effective amount of at least one phase 2 gene inducer.2. The composition of claim 1 , wherein the at least one phase 2 gene inducer and/or an analogue or derivative thereof are selected from the class of molecules consisting of isothiocyanates claim 1 , naphthoquinones claim 1 , sesquiterpenes and stilbenes and salts claim 1 , solvates or derivatives thereof.3. The composition of claim 2 , wherein the at least one phase 2 gene inducer is a phytochemical.4. The composition of claim 2 , wherein the at least one phase 2 gene inducer is selected from the group consisting of sulforaphane claim 2 , shikonin claim 2 , zerumbone claim 2 , reservatrol claim 2 , phenethyl isothiocyanate (PEITC) claim 2 , allyl isothiocyanate (AITC) claim 2 , hydroxytyrosol claim 2 , curcumin claim 2 , 6-gingerol claim 2 , capsaicin claim 2 , genistein claim 2 , Bis(2-hydroxybenzylidene) ...

Method for Treating Phytophotodermatitis

A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 14-. (canceled)5. A method for treating phytophotodermatitis , comprising the step(s) of:applying a lysine derivative to an area affected by phytophotodermatitis, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.610-. (canceled)11. The method for treating phytophotodermatitis claim 5 , according to claim 5 , further comprising the step of applying an additional surfactant claim 5 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 5 , an anionic surfactant claim 5 , a cationic surfactant claim 5 , a zwitterionic surfactant claim 5 , and combinations thereof. This application is a continuation of U.S. application Ser. No. 14/594,788, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 12, 2015, which is a continuation of U.S. application Ser. No. 13/342,516, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2012, now U.S. Pat. No. 8,933,119, which claims the benefit of U.S. Provisional Application Ser. No. 61/429,325, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2011 and U.S. Provisional Application Ser. No. 61/502,067, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jun. 28, 2011—all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present ...

Method for Treating Phytophotodermatitis

A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 15-. (canceled)710-. (canceled)11. The method for treating phytophotodermatitis claim 6 , according to claim 6 , further comprising the step of applying an additional surfactant claim 6 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 6 , an anionic surfactant claim 6 , a cationic surfactant claim 6 , a zwitterionic surfactant claim 6 , and combinations thereof. This application is a continuation of U.S. application Ser. No. 14/594,788, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 12, 2015, which is a continuation of U.S. application Ser. No. 13/342,516, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2012, now U.S. Pat. No. 8,933,119, which claims the benefit of U.S. Provisional Application Ser. No. 61/429,325, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2011 and U.S. Provisional Application Ser. No. 61/502,067, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jun. 28, 2011-all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present invention relates in general to a method for treating phytophotodermatitis and, more particularly, to a method for treating phytophotodermatitis caused by exposure to linear and/or non-linear (e.g., angular) furanocoumarins and derivatives thereof—among other chemical compounds.2. Background ArtPhytophotodermatitis (hereinafter sometimes referred to “PPD”) is traditionally expressed as a cutaneous phototoxic inflammatory response and/or eruption ...

Method for Treating Phytophotodermatitis

A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 16-. (canceled)89-. (canceled)11. The method for treating phytophotodermatitis claim 7 , according to claim 7 , further comprising the step of applying an additional surfactant claim 7 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 7 , an anionic surfactant claim 7 , a cationic surfactant claim 7 , a zwitterionic surfactant claim 7 , and combinations thereof.12. The method for treating phytophotodermatitis claim 10 , according to claim 10 , further comprising the step of applying an additional surfactant claim 10 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 10 , an anionic surfactant claim 10 , a cationic surfactant claim 10 , a zwitterionic surfactant claim 10 , and combinations thereof. This application is a continuation of U.S. application Ser. No. 14/594,788, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 12, 2015, which is a continuation of U.S. application Ser. No. 13/342,516, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2012, now U.S. Pat. No. 8,933,119, which claims the benefit of U.S. Provisional Application Ser. No. 61/429,325, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2011 and U.S. Provisional Application Ser. No. 61/502,067, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jun. 28, 2011—all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present invention relates in general to a method ...

Pharmaceutical Formulation of Racecadotril

The object of the present invention is a pharmaceutical formulation of racecadotril characterized by high bioavailability. In particular, the present invention relates to a method of dry granulating racecadotril in the presence of a hydrophilic excipient and a disintegrant, preferably with a low moisture content; said method being carried out by means of a tablet machine or alternately a roller compacting machine, carrying out the compaction step with a compaction strength of less than 30 kN and equal to or greater than 4 kN, and the step of grinding the slugs and screening so as to obtain a granulate in which not more than 50% by weight of the product has a particle size of less than 90 micron.

METHOD FOR TREATING PSORIASIS

A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 112-. (canceled)13. A method for treating psoriasis , comprising the step of:applying a lysine derivative to an area affected by psoriasis, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.14. The method for treating psoriasis claim 13 , according to claim 13 , wherein the psoriasis is selected from one of the groups comprising plaque psoriasis claim 13 , guttate psoriasis claim 13 , inverse psoriasis claim 13 , pustular psoriasis claim 13 , erythrodermic psoriasis claim 13 , scalp psoriasis claim 13 , and/or nail psoriasis.15. A method for treating psoriasis claim 13 , comprising the step of:administering a lysine derivative to a patient affected by psoriasis, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.16. The method for treating psoriasis claim 15 , according to claim 15 , wherein the psoriasis is selected from one of the groups comprising plaque psoriasis claim 15 , guttate psoriasis claim 15 , inverse psoriasis claim 15 , pustular psoriasis claim 15 , erythrodermic psoriasis claim 15 , scalp psoriasis claim 15 , and/or nail psoriasis. This application is a continuation of U.S. application Ser. No. 16/742,122, entitled ...

REGULATION OF CANCER USING NATURAL COMPOUNDS AND/OR DIET

The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout. 1. A method of treating a subject for a proliferative disease , comprising:a) administering to the subject in need of such treatment, an effective amount of a composition comprising epigallocatechin-3-gallate, a composition comprising curcumin, and a composition comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and/or sulforaphane (SFN), and, optionally, providing a modified ketogenic diet or a ketogenic diet to the subject; orb) providing a modified ketogenic diet or a ketogenic diet to the subject; and, optionally, administering to the subject in need of such treatment, an effective amount of a composition comprising epigallocatechin-3-gallate, a composition comprising curcumin, and a composition comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and/or sulforaphane (SFN).2. The method of claim 1 , wherein the proliferative disease is a cancer.3. The method of claim 2 , wherein the proliferative disease is a cancer is selected from the group consisting of Acute Lymphoblastic Leukemia claim 2 , Acute Myeloid Leukemia claim 2 , Adrenocortical Carcinoma claim 2 , AIDS-Related Cancers claim 2 , AIDS-Related Lymphoma claim 2 , Anal Cancer claim 2 , Appendix Cancer claim 2 , ...

PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS

Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. 170.-. (canceled)71. A topical dermal lotion , cream foam or gel suitable for use in treating joint or cartilaginous inflammation or pain due to mechanical stress comprising a therapeutically effective amount of a selective PPARα agonist and a phase 2 gene activator and one or more additives and adjuvants in an amount effective to treat joint or cartilaginous inflammation or pain in a subject in need thereof.72. The composition of claim 71 , wherein said selective PPARα is selected from the group consisting of Wy14643 claim 71 , clofibrate claim 71 , fenofibrate claim 71 , 8(S) Hydroxy-(5Z claim 71 ,9E claim 71 ,11Z claim 71 ,14Z)-eicosatetraenoic acid (8(S)-HETE) claim 71 , leukotriene B4 (LTB4) claim 71 , tetradecythioacetic acid (TTA) claim 71 , GW 9578 claim 71 , and GW 7647.73. The composition of claim 71 , wherein said phase 2 gene activator comprises a glucosinolate or isothyocyanate.75. The composition of claim 71 , wherein the joint or cartilaginous inflammation or pain is due to osteoarthritis.76. A method for treating or preventing joint or cartilaginous inflammation or pain in a mammal due to mechanical stress comprising administering a therapeutically effective amount of the composition of to the mammal.771. The method of claim 76 , wherein 0.05-150 mg/kg/day of said selective PPARα agonist of claim is administered.78. The method of claim 77 , wherein said phase 2 gene activator comprises a glucosinolate or isothyocyanate.79. The method of claim 78 , wherein 1-50 mg/kg/day of said glucosinolate is administered.81. The method of claim 76 , wherein said administration is topical.82 ...

Method for Treating Eczema

A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 1. A method for treating eczema , comprising the step(s) of:applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.2. The method for treating eczema according to claim 1 , further comprising the step of removing the isothiocyanate functional surfactant from the area affected by eczema.312-. (canceled) This application is a continuation of U.S. application Ser. No. 13/348,821, entitled “METHOD FOR TREATING ECZEMA,” filed Jan. 12, 2012, which claims the benefit of U.S. Provisional Application Ser. No. 61/431,977, entitled “METHOD FOR TREATING ECZEMA,” filed Jan. 12, 2011 and U.S. Provisional Application Ser. No. 61/502,113, entitled “METHOD FOR TREATING ECZEMA,” filed Jun. 28, 2011—all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present invention relates in general to a method for treating eczema (i.e., dermatitis) and, more particularly, to a method for treating a plurality of forms of eczema including, but not limited to, atopic eczema.2. Background ArtEczema is a general term for many types of skin inflammation, also known as dermatitis. The most common form of eczema is atopic eczema or dermatitis (n.b., many practitioners use the terms eczema and dermatitis interchangeably). However, there are many other different forms of eczema including, contact eczema, allergic contact eczema, seborrheic eczema, nummular ...

MULTIVITAMIN CAPABLE OF BENEFICIAL GENE REGULATION THROUGH MICRORNA (MIRNA)

The present invention includes compositions and methods for modifying the expression of microRNAs comprising: one or more plant secondary metabolites capable of beneficially regulating different genes in the human genome by modifying the expression of one or more microRNAs, wherein the one or more plant secondary metabolites are selected and provided in an amount selected to target the modification of one or more specific microRNA. 1. A composition for modifying the expression of microRNAs comprising:one or more plant secondary metabolites capable of beneficially regulating different genes in the human genome by modifying the expression of one or more microRNAs, wherein the one or more plant secondary metabolites are selected and provided in an amount selected to target the modification of one or more specific microRNAs.2. The composition of claim 1 , wherein the plant secondary metabolite is selected from at least 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , 9 claim 1 , or 10 plant secondary metabolites selected from epigallocatechin gallate; isoquercetin; folic acid; curcumin; hesperidin; grape polyphenols; sulporaphane; proanthocyanidins; apple polyphenols; or citrus bioflavonoids.3. The composition of claim 1 , wherein the composition is in capsule claim 1 , tablet claim 1 , gel claim 1 , powder claim 1 , pill claim 1 , granules claim 1 , solution claim 1 , suspension claim 1 , softgel claim 1 , gummy claim 1 , chewable claim 1 , liquid claim 1 , cake claim 1 , paste claim 1 , fast melting tablet claim 1 , film claim 1 , bead claim 1 , or bar form.4. The composition of claim 1 , wherein the composition further comprises at least one of one or more nutritional or therapeutic excipients claim 1 , salts claim 1 , corrigents claim 1 , fillers claim 1 , buffers claim 1 , diluents claim 1 , binders claim 1 , lubricants claim 1 , sweeteners claim 1 , coloring agents claim 1 , flavoring agents claim 1 , emulsifiers claim 1 , ...

INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 1. A method for reducing macrophage migration inhibitory factor cytokine or its biological activity , comprising the step of:administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.2. The method according to claim 1 , wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.3. The method according to claim 1 , wherein the isothiocyanate functional surfactant comprises a lysine derivative claim 1 , wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen claim 1 , and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen claim 1 , and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.12. The method according to claim 1 , wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally claim 1 , intravenously claim 1 , intramuscularly claim 1 , intrathecally claim 1 , cutaneously claim 1 , subcutaneously claim 1 , transdermally claim 1 , sublingually claim 1 , buccally claim 1 , rectally claim 1 , vaginally claim 1 , ocularly claim 1 , otically claim 1 , and nasally.13. The method according to claim 12 , wherein the amount of isothiocyanate functional surfactant topically ...

METHOD FOR TREATING AUTISM AND OTHER NEURODEVELOPMENTAL DISORDERS

A method for treating autism and other neurodevelopmental disorders including the step of administering an effective amount of an isothiocyanate functional surfactant to a human, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. The administration of the isothiocyanate functional surfactant may be augmented with a NMDA-receptor antagonist and/or a TNF-α inhibiting agent. 1. A method for treating autism or other neurodevelopmental disorders , comprising the step(s) of:administering to a patient in need thereof an effective amount of an isothiocyanate functional surfactant, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.2. The method for treating autism or other neurodevelopmental disorders according to claim 1 , further comprising the step of administering a NMDA-receptor antagonist to the patient.3. The method for treating autism or other neurodevelopmental disorders according to claim 2 , wherein the NMDA-receptor antagonist comprises 1-amino-3 claim 2 ,5-dimethyladamantane or a pharmaceutically acceptable salts thereof.4. The method for treating autism or other neurodevelopmental disorders according to claim 2 , further comprising the step of administering a TNF-α inhibiting agent to the patient.5. The method for treating autism or other neurodevelopmental disorders according to claim 4 , wherein the TNF-α inhibiting agent is selected from at least one of Lenalinomide claim 4 , Thalidomide claim 4 , L-Camosine claim 4 , Infliximab claim 4 , Etanercept claim 4 , a stem cell preparation claim 4 , derivatives thereof claim 4 , isomers thereof claim 4 , or pharmaceutically acceptable salts thereof.6. The method for treating autism or other neurodevelopmental ...

PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS

Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. 1. A topical dermal lotion , cream foam or gel suitable for use in treating joint or cartilaginous inflammation or pain comprising a therapeutically effective amount of Wy14643 and sulforaphane and one or more additives and adjuvants in an amount effective to treat joint or cartilaginous inflammation or pain in a subject in need thereof , wherein the joint or cartilaginous inflammation or pain is due to osteoarthritis.2. The composition of claim 1 , wherein the therapeutically effective amount is from about 0.05 to about 150 mg/Kg/day of Wy14643 and from about 1 to about 150 mg/Kg/day of sulforaphane.3. The composition of claim 1 , wherein the therapeutically effective amount is from about 0.05 to about 4.0 mg/Kg/day of Wy14643 and from about 5 to about 50 mg/Kg/day of sulforaphane.4. A method for treating or preventing joint or cartilaginous inflammation or pain in a mammal due to mechanical stress comprising administering a therapeutically effective amount of the composition of to the mammal.5. The method of claim 1 , wherein 0.05-150 mg/kg/day of said selective Wy1463 of is administered.6. The method of claim 4 , wherein said administration is topical.7. The method according to claim 4 , wherein said joint is a hip claim 4 , a knee claim 4 , an ankle claim 4 , a shoulder claim 4 , an elbow claim 4 , a wrist or a joint of a foot claim 4 , a joint of a hand claim 4 , or a joint of the spine.8. The method according to claim 4 , wherein said joint is the temporomandibular joint. The application claims benefit of priority to U.S. Provisional Patent Application No. 60/796,198, filed May 1, 2006, ...

Combination Compositions and Therapies Comprising 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, and Methods of Making and Using Same

This disclosure provides, among other things, compositions comprising quantities of oltipraz, either in recrystallized or formulated crystal form, and a composition that reduces the rate of cellular oxygen consumption such as atovaquone, as well as methods of making such compositions, and methods of treating patients using such compositions. This disclosure also provides, among other things, compositions comprising quantities of oltipraz, either in recrystallized or formulated crystal form, for use in treating patients who may experience ischemia and/or reperfusion injury. 1. A composition which comprises (i) an active pharmaceutical ingredient that reduces the rate of cellular oxygen consumption (OCR-API) and (ii) 4-methyl-5-(pyrazin-2-yl)-3H-1 ,2-dithiole-3-thione (oltipraz) or a pharmaceutically acceptable salt thereof.2. A composition according to claim 1 , wherein the active pharmaceutical ingredient that reduces the rate of cellular oxygen consumption is selected from atovaquone claim 1 , a ubiquinone analogue other than atovaquone claim 1 , meclizine claim 1 , nimorazole claim 1 , metformin claim 1 , phenformin claim 1 , antimycin A claim 1 , pyrvinium claim 1 , berberine claim 1 , niclosamide claim 1 , acriflavinium claim 1 , sorafenib claim 1 , emetine claim 1 , plicamycin claim 1 , suloctidil claim 1 , pentamidine claim 1 , amsacrine claim 1 , irinotecan claim 1 , itraconazole claim 1 , mitomycin claim 1 , hydroxyprogesterone claim 1 , cyclosporine claim 1 , fenofibrate and pharmaceutically acceptable salts thereof.3. A composition according to claim 1 , wherein the OCR-API is atovaquone.4. A composition according to claim 1 , wherein the composition comprises (i) atovaquone and (ii) oltipraz.5. A composition according to claim 1 , wherein the composition comprises (ii) a quantity of crystals of oltipraz having an intensity averaged claim 1 , mean hydrodynamic diameter (Z-average) (“MHD”) of from 30 to 2000 nm claim 1 , as measured by dynamic light ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The pharmaceutical composition of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris COR claim 1 , lower alkyl substituted by —CO(lower alkyl) claim 1 , lower alkyl substituted with —CO(lower alkoxyalkyl) claim 1 , lower alkoxyalkyl substituted with —CO(lower alkyl) claim 1 , or lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl).3. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , and Ris H.4. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , Ris COR claim 2 , and -d-Rand -e-Rare not both —O-(lower alkyl) or —O-(lower alkoxyalkyl).5. The pharmaceutical composition of claim 1 , wherein{'sub': '17', '(a) Ris lower alkyl;'}{'sub': 18', '2', '10, '(b) Ris CN or COR;'}{'sub': 11', '12', '13, 'claim-text': (i) —O-(lower alkyl);', {'sub': '2', '(ii) —O-(lower alkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(iii) —O-(lower alkyl substituted with —CO(lower alkoxyalkyl));'}, '(iv) —O-(lower alkyl substituted with fluorine or chlorine);', '(v) —O-(lower alkoxyalkyl);', {'sub': '2', '(vi) —O-(lower alkoxyalkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(vii) —O-(lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl));'}, '(viii) —O-(lower alkyl substituted with fluorine or chlorine); or', {'sub': 2', '10, '(ix) -(single bond)-COR; and'}], '(c) at least one ...

Sensory Stimulation for Cessation of Eating

Methods and compositions are provided for modifying the eating behavior of an individual. The compositions provide an oral stimulatory effect such as tingling, cooling, and/or warming. Consumption of the compositions after eating a desired amount of food may habituate the individual to ending a meal and serve to cue cessation of eating, assisting the individual with ending a meal at a time point before a signal of satiety has reached the brain. Consumption of the composition in lieu of snacking between meals may assist the individual with avoiding consumption of snacks. 1. A method for modifying eating behavior in an individual , said method comprising:orally consuming a composition after consuming an amount of food, wherein the composition causes at least one oral sensation in the individual that makes consuming a further amount of food undesirable, wherein the individual acquires a habitual sense of meal completion after consuming said composition after each meal for a period of time.24.-. (canceled)5. A method according to claim 1 , wherein the sense of meal completion lasts at least until the individual acquires a feeling of satiety without further consumption of food.6. A method according to claim 1 , wherein the composition stimulates the third division of the trigeminal nerve claim 1 , and wherein said stimulation of the trigeminal nerve cues the cessation of eating.78.-. (canceled)9. A method according to claim 1 , wherein the oral sensation comprises at least two sensations selected from tingling claim 1 , cooling claim 1 , and warming.1011.-. (canceled)12. A method according to claim 9 , wherein the oral sensation comprises a tingling sensation that is provided by at least one compound selected from spilanthol claim 9 , isobutylalkylamide claim 9 , and hydroxyl-alpha sanshool.13. A method according to claim 9 , wherein the oral sensation comprises a cooling sensation that is provided by menthol or a derivative thereof.14. A method according to claim 9 , ...

ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE

An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: 1. A surfactant formulation , comprising:an isothiocyanate functional surfactant, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant; anda non-hygroscopic solvent.2. A surfactant formulation , comprising:a lysine derivative, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen; anda non-hygroscopic solvent. This application is a continuation-in-part of U.S. application Ser. No. 15/297,304, entitled “ISOTHIOCYANATE FUNCTIONAL SURFACTANT FORMULATION AND ASSOCIATED METHOD OF USE,” filed Oct. 19, 2016, which is a continuation of U.S. application Ser. No. 14/594,788, filed Jan. 12, 2015, which is a continuation of U.S. application Ser. No. 13/342,516, filed Jan. 3, 2012, now U.S. Pat. No. 8,933,119, which claims the benefit of U.S. Provisional Application Ser. No. 61/502,067, filed Jun. 28, 2011, and U.S. Provisional Application Ser. No. 61/429,325, filed Jan. 3, 2011—all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.Not applicable.Not applicable.1. Field of the InventionThe present invention relates in general to isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants, and associated methods of use—including, but not limited to, chemopreventive, chemotherapeutic and/or chemoprotective applications.2. Background ArtNatural, semi-synthetic, and/or synthetic compounds having one or more isothiocyanate functional groups and ...

H2S-BASED THERAPEUTIC AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in the early stage of Parkinson's Disease as well as in Alzheimer's Disease. 2. The compound for use according to claim 1 , wherein A is —N═C═S.3. The compound for use according to claim 1 , wherein A is —NH—B.4. The compound for use according to claim 3 , wherein n is preferably 1.5. The compound for use according to claim 1 , wherein the neurodegenerative disease is a disease selected from the group consisting of Parkinson's disease claim 1 , Alzheimer's disease amyotrophic lateral sclerosis and Huntington's disease7. The compound of claim 6 , wherein n is 1.9. The pharmaceutical composition according to claim 8 , wherein A is —N═C═S. The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in the early stages of Parkinson's Disease as well as in Alzheimer's Disease.Hydrogen sulfide (HS) is emerging as a hot topic in the field of drug discovery. HS is a well-known pungent and toxic gas and has been recognized as the third gaseous signaling molecule in addition to nitric oxide and carbon monoxide [1]. HS is produced endogenously from the amino acids L-cysteine and homocysteine by several enzymes. In particular, in the brain it is synthesized by cystathionine-b-synthetase (CBS) which is highly expressed in the hippocampus and cerebellum [2]. Noteworthy, a dramatic decrease of CBS activity and a consequent drastic fall in HS levels (about 50%) have been detected in the brain of patients affected by Alzheimer's disease (AD). Moreover, it seems to play a neuroprotective role in Parkinson's disease [3], thus suggesting that this gaseous-transmitter is able to ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The method of claim 1 , wherein said ischemic heart condition is selected from the group consisting of stable angina claim 1 , unstable angina and vasospastic angina3. The method of claim 1 , wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation claim 1 , atrial flutter claim 1 , paroxysmal supraventricular tachycardia (PSVT) claim 1 , premature atrial claim 1 , nodal claim 1 , or ventricular depolarizations claim 1 , atrial tachycardia claim 1 , ventricular tachycardia claim 1 , ventricular fibrillation claim 1 , and Torsades de Pointes. The invention relates to the use of phenylalkylamine compounds which block L-type calcium channels to treat cardiovascular disorders.Calcium channel blockers (CCBs) are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias and include a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. Calcium influx through these channels initiates a process of electromechanical coupling that ultimately leads to muscle contraction. The ability to regulate the entry of calcium into cardiac and vascular smooth muscle cells is a powerful therapeutic approach to the treatment of angina and hypertension, respectively. Likewise, blocking calcium influx into cardiac tissues ...

METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 120-. (canceled)25. The method according to claim 21 , wherein the patient is a mammal.26. The method according to claim 21 , wherein the mammal is a human.31. The method according to claim 27 , wherein the patient is a mammal.32. The method according to claim 27 , wherein the mammal is a human.37. The method according to claim 33 , wherein the patient is a mammal.38. The method according to claim 33 , wherein the mammal is a human. This application is a continuation of U.S. application Ser. No. 16/025,640, entitled “METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS” filed Jul. 2, 2018, which is a continuation-in-part of U.S. application Ser. No. 15/838,444, entitled “METHOD FOR TREATING BLADDER CANCER” filed Dec. 12, 2017, now U.S. Pat. No. 10,111,852, which is a continuation of U.S. application Ser. No. 15/423,869, entitled “METHOD FOR TREATING BLADDER CANCER” filed Feb. 3, 2017, now U.S. Pat. No. 9,839,621, which is a continuation-in-part of U.S. application Ser. No. 14/867,626, entitled “METHOD FOR TREATING SKIN CANCER,” filed Sep. 28, 2015, now U.S. Pat. No. 9,642,827, which is a continuation of U.S. application Ser. No. 14/867,585, entitled “METHOD FOR TREATING SKIN CANCER,” filed Sep. 28, 2015, now U.S. Pat. No. 9,636,320, which is a continuation of U.S. application Ser. No. 14/519,510, entitled “METHOD FOR TREATING SKIN CANCER,” filed Oct. 21, 2014, now U.S. Pat. No. 9,504,667, which is a continuation of U.S. application Ser. No. 13/952,236, entitled “METHOD FOR TREATING SKIN CANCER,” filed Jul. 26, 2013, now U.S. Pat. No. 8,865,772, which claims the benefit of U.S. Provisional Application Ser. No. 61/676,093, entitled “METHOD FOR ...

TWO-LAYER OCULAR IMPLANT

The present invention generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye. 1. A method for forming a molded two-layer ocular implant , the implant comprising a therapeutic agent for treatment or prevention of a disorder of the eye , the method comprising:(a) dispensing a polymer into a curved depression on a mold body to form a polymer layer having a curved external surface in contact with the bottom of the curved depression and further comprising an exposed upper surface;(b) generating a curvature in the exposed upper surface of the polymer layer, thereby forming a curved polymer layer interface surface;(c) curing the polymer layer, thereby providing a hardened curved polymer layer interface surface;(d) dispensing a silicone adhesive comprising the therapeutic agent dispersed therein onto the hardened interface surface to provide a silicone layer with an exposed surface;(e) generating a curvature in the exposed surface of the silicone layer thereby forming a curved eye-contacting surface; and(f) curing the silicone layer such that the first layer and second layer are fixed to each other, thereby forming the molded two-layer ocular implant.2. The method of wherein the implant is circular or oval-shaped.3. The method of wherein steps b) and e) are performed using an impression body with a curved protrusion for generating the curvature in the exposed ...

Methods and compositions for reducing alcohol toxicity

The present invention comprises methods and compositions for reducing ethanol toxicity due to accumulation of acetaldehyde in a cell. A method comprises administering to a cell a composition comprising a compound that increases the expression, the amount of, and/or the activity of at least one member of the aldehyde dehydrogenase superfamily.

METHOD FOR PREVENTING OR TREATING HANGOVER SYMPTOM(S) ASSOCIATED WITH CONSUMPTION OF ALCOHOLIC BEVERAGE(S)

The invention provides methods for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in a subject comprising administering an aldehyde sequestering agent so as to reduce or counter blood aldehyde buildup in the subject, thereby preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in the subject. 1. A method for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in a subject comprising administering an aldehyde sequestering agent in an effective amount so as to reduce or counter blood aldehyde buildup in the subject , thereby preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in the subject.2. The method of claim 1 , wherein the alcoholic beverage(s) comprise one or more congener(s).3. The method of claim 2 , wherein the congener is selected from the group consisting of aldehyde claim 2 , fusel oil and a combination thereof.4. (canceled)5. The method of claim 1 , wherein the fusel oil comprises a mixture of two or more alcohols.6. The method of claim 5 , wherein the fusel oil is a fermentation product comprising C3 or higher chain length aliphatic alcohols.7. The method of claim 1 , wherein the fusel oil comprises two or more alcohols selected from the group consisting of isopentyl (isoamyl) alcohol claim 1 , 2-methyl-1-butanol claim 1 , isobutyl alcohol claim 1 , n-propyl alcohol claim 1 , butyl alcohol claim 1 , hexanol and a combination thereof.8. The method of claim 1 , wherein the blood aldehyde is selected from the group consisting of aldehyde congener claim 1 , metabolite of fusel oil and a combination thereof.9. The method of claim 8 , wherein the aldehyde congener is selected from the group consisting of acetaldehyde claim 8 , furfural claim 8 , alkyl aldehyde claim 8 , aryl aldehyde and a combination thereof.10. The method of claim 8 , wherein the metabolite of fusel oil comprises ...

MEDICINE FOR COVID-19 AND TREATMENT

The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The pharmaceutical composition of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris COR claim 1 , lower alkyl substituted by —CO(lower alkyl) claim 1 , lower alkyl substituted with —CO(lower alkoxyalkyl) claim 1 , lower alkoxyalkyl substituted with —CO(lower alkyl) claim 1 , or lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl).3. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , and Ris H.4. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , Ris COR claim 2 , and -d-Rand -e-Rare not both —O-(lower alkyl) or —O-(lower alkoxyalkyl).5. The pharmaceutical composition of claim 1 , wherein{'sub': '17', '(a) Ris lower alkyl;'}{'sub': 18', '2', '10, '(b) Ris CN or COR;'}{'sub': 11', '12', '13, 'claim-text': (i) —O-(lower alkyl);', {'sub': '2', '(ii) —O-(lower alkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(iii) —O-(lower alkyl substituted with —CO(lower alkoxyalkyl));'}, '(iv) —O-(lower alkyl substituted with fluorine or chlorine);', '(v) —O-(lower alkoxyalkyl);', {'sub': '2', '(vi) —O-(lower alkoxyalkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(vii) —O-(lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl));'}, '(viii) —O-(lower alkyl substituted with fluorine or chlorine); or', {'sub': 2', '10, '(ix) -(single bond)-COR; and'}], '(c) at least one ...

Compositions and Methods for Treating Autism Spectrum Disorders

The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivative thereof) or (2) a glucosinolate, and optionally, an enzyme, to thereby treat an autism spectrum disorder and/or reduce the severity of at least one symptom of the disorder. Methods for preparing such compositions are also featured. 1. A method for treating an autism spectrum disorder in a human , the method comprising administering to the human daily a composition comprising an effective amount of an isothiocyanate , to thereby treat the disorder , wherein the effective amount is: between 25 and 75 μmol if the human weighs 100 pounds or less; between 75 and 125 μmol if the human weighs between 101 to 199 pounds; or between 125 and 175 μmol if the human weighs more than 200 pounds.2. The method of claim 1 , wherein the amount is 50 μmol claim 1 , if the human weighs 100 pounds or less; 100 μmol if the human weighs between 101-199 pounds; or 150 μmol if the human weighs more than 200 pounds.3. The method of claim 1 , wherein the amount is administered daily as one dose.4. The method of claim 1 , wherein the amount is administered daily as more than one dose.5. The method of claim 1 , wherein the isothiocyanate is administered to the human for at least 18 weeks.6. The method of claim 1 , wherein the disorder is autism.7. The method of claim 6 , wherein the human has moderate to severe autism.8. The method of claim 1 , wherein the amount is effective to reduce the severity of one or more behavioral symptoms of the disorder.9. The method of claim 1 , wherein the human has a medical history of behavioral improvements with fever.10. The method of claim 1 , wherein the isothiocyanate is sulforaphane or a derivative thereof.11. The method of claim 10 , wherein the sulforaphane is enantiopure for the (R) enantiomer.12. The method of claim 1 ...

METHOD FOR TREATING BLADDER CANCER

A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 112-. (canceled)13. A method for treating bladder cancer , comprising the step(s) of:administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.14. The method for treating bladder cancer claim 13 , according to claim 13 , further comprising the step of administering an additional surfactant claim 13 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 13 , an anionic surfactant claim 13 , a cationic surfactant claim 13 , a zwitterionic surfactant claim 13 , and combinations thereof.15. The method for treating bladder cancer claim 13 , according to claim 13 , wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma claim 13 , transitional cell carcinoma claim 13 , papillary carcinomas claim 13 , flat carcinoma claim 13 , squamous cell carcinoma claim 13 , adenocarcinoma claim 13 , small cell carcinoma claim 13 , and sarcoma.16. The method for treating bladder cancer claim 15 , according to claim 15 , further comprising the step of administering an additional surfactant claim 15 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 15 , an anionic surfactant claim 15 , a cationic surfactant claim 15 , a zwitterionic surfactant claim 15 , and combinations thereof.17. A method for treating bladder cancer claim 15 , ...

METHOD FOR PREVENTING AND/OR TREATING HAIRY WART DISEASE

Provided is a novel method for preventing and/or treating hairy wart disease which is a hoof and leg disease of ungulates. The method is carried out by administering an isothiocyanic acid ester such as allyl isothiocyanate to a hoof of an ungulate. Examples of ungulates targeted for application of the present invention include cows such as dairy cows as well as sheep, pigs and horses. 1. A method for preventing and/or treating hairy wart disease by administering an isothiocyanic acid ester to a hoof of an ungulate.2. The method according to claim 1 , wherein the isothiocyanic acid ester is a Calkenyl isothiocyanate claim 1 , aryl isothiocyanate claim 1 , Calkyl isothiocyanate claim 1 , phenyl Calkyl isothiocyanate or Ccycloalkyl isothiocyanate.3. The method according to claim 1 , wherein the isothiocyanic acid ester is a Calkenyl isothiocyanate.4. The method according to claim 1 , wherein the isothiocyanic acid ester is allyl isothiocyanate.5. The method according to claim 1 , wherein the isothiocyanic acid ester is administered to a hoof of an ungulate after hoof trimming.6. A preventive and/or therapeutic agent for hairy wart disease claim 1 , comprising an isothiocyanic acid ester as an active ingredient thereof. The present invention relates to a method for preventing and/or treating hairy wart disease which is a hoof and leg disease of ungulates.Hairy wart disease is an infectious disease that propagates among cows and other ungulates. Digital dermatitis (DD) is known to be a particularly serious hoof and leg disease caused by bacteria belonging to the genus , and in the case dairy cows have become afflicted with this disease, can lead to serious gait disorders or weight loss and the like as well as cause decreased milk production, thereby making it a serious problem in numerous dairy product-producing countries including Japan. As methods used to prevent and/or treat hairy wart disease in dairy cows, a foot bath wherein hoof baths containing medicinal agents, ...

SULFORAPHANE-DERIVED COMPOUNDS, PRODUCTION METHOD THEREOF AND THE MEDICAL, FOOD AND COSMETIC USE OF SAME

The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins. 4. The compound according to claim 1 , where Xis oxygen and Z is sulphur.5. The compound according to claim 1 , where R is selected from a saturated linear alkyl chain and a branched alkyl chain.6. The compound according to claim 5 , where R is a methyl group.7. The compound according to claim 1 , where the value of n is equal to the value of m.8. The compound according to claim 7 , where n and m are equal to 1.9. The compound according to claim 7 , where p is between 1 and 3 inclusive.11. The method according to claim 10 , where the triarylphosphine is triphenylphosphine.14. The method according to claim 10 , where the chiral secondary alcohol derived from carbohydrates is derived from glucofuranose.15. The method according to claim 10 , where Yis a sulphonate.16. The method according to claim 15 , where Yis mesylate or triflate.17. The method according to claim 10 , where R′OH is diacetone-D-glucose.18. The method according to claim 10 , where R is methyl.19. The method according to claim 10 , where the sterically hindered base is a trialkylamine claim 10 , and the base that is not sterically hindered is an aromatic amine.20. The method according to claim 19 , where the sterically hindered base is ...

METHOD OF SYNTHESISING SULFORAPHANE

The present invention relates to a method of synthesising sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesising a stabilised complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent. 2. A process according to claim 1 , wherein the solvent is water.3. A process according to or claim 1 , wherein the oxidizing agent is hydrogen peroxide or a water soluble or miscible organic per-acid claim 1 , or a mixture thereof.4. A process according to claim 3 , wherein the oxidising agent is hydrogen peroxide.5. A process according to any one of the preceding claims claim 3 , wherein the catalyst is selected from cyclodextrin and organic or inorganic acids claim 3 , such as ascorbic acid claim 3 , formic acid claim 3 , acetic acid claim 3 , and/or sulphuric acid.6. A process according to claim 5 , wherein the catalyst is a cyclodextrin.7. A process according to claim 6 , wherein the catalyst is alpha-cyclodextrin.8. A process according to any one of the preceding claims claim 6 , wherein 0.0001 to 1.0 molar equivalents of catalyst are present (relative to the compound of formula A).9. A process according to any one of the preceding claims claim 6 , wherein in step (i) the temperature of the reaction is maintained at a temperature of 25° C. or less or 15° C. or less when the oxidising agent is added to the reaction mixture.10. A process according to any one of the preceding claims claim 6 , wherein the cyclodextrin used in step (ii) is selected from one or more of W6 (alpha) cyclodextrin (a six sugar ring molecule) claim 6 , W7 (beta) cyclodextrin (a seven sugar ring molecule) claim 6 , W8 (gamma) cyclodextrin (an eight sugar ring molecule) claim 6 , derivatives thereof claim 6 , and mixtures thereof.11. A process according to claim 10 , wherein the ...

Method for Treating Psoriasis

A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 1. A method for treating psoriasis , comprising the step(s) of:applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.2. The method for treating psoriasis according to claim 1 , further comprising the step of removing the isothiocyanate functional surfactant from the area affected by psoriasis.3. A method for treating psoriasis claim 1 , comprising the steps of:applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant;removing the isothiocyanate functional surfactant from the area affected by psoriasis; andrepeating the steps of applying and removing the isothiocyanate functional surfactant to/from the affected area.4. A method for treating psoriasis claim 1 , comprising the steps of:washing an area affected by psoriasis with an isothiocyanate functional surfactant, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.5. A method for treating psoriasis claim 1 , comprising the step(s) of:applying a lysine derivative to an area affected by psoriasis, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and ...

ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING BENIGN NEOPLASMS, IN SITU NEOPLASMS, MALIGNANT NEOPLASMS, AND NEOPLASMS OF UNCERTAIN OR UNKNOWN BEHAVIOR

A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent. 1. A medicament formulation , comprising:a first medicament, wherein the first medicament comprises an isothiocyanate functional surfactant; anda second medicament, wherein the second medicament comprises an antineoplastic agent.2. The medicament formulation according to claim 1 , wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.3. The medicament formulation according to claim 1 , wherein the isothiocyanate functional surfactant comprises a lysine derivative claim 1 , wherein the lysine derivative comprises an a-nitrogen and a ε-nitrogen claim 1 , and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the a-nitrogen claim 1 , and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.12. The medicament formulation according to claim 1 , wherein the second medicament comprises at least one of a cytotoxic antineoplastic agent and a targeted antineoplastic agent.13. The medicament formulation according to claim 1 , wherein the second medicament comprises a cytotoxic antineoplastic agent selected from the group comprising a nucleoside analogue claim 1 , an antifolate claim 1 , an antimetabolite claim 1 , a topoisomerase inhibitor claim 1 , a anthracycline claim 1 , a podophyllotoxin claim 1 , a taxane claim 1 , a vinca alkaloid claim 1 , an alkylating agent claim 1 , and/or a platinum compound.14. The medicament formulation according to claim 1 , wherein the second medicament comprises a monoclonal antibody ...

Cadotril particles

Cadotril particles suitable for solid or liquid dosage forms are disclosed

Method for Treating Phytophotodermatitis

A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 1. A method for treating phytophotodermatitis , comprising the step(s) of:applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.2. The method for treating phytophotodermatitis according to claim 1 , further comprising the step of removing the isothiocyanate functional surfactant from the area affected by phytophotodermatitis.3. (canceled)4. A method for treating phytophotodermatitis claim 1 , comprising the steps of:washing an area affected by phytophotodermatitis with an isothiocyanate functional surfactant, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.5. (canceled)711-. (canceled) This application is a continuation of U.S. application Ser. No. 13/342,516, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2012, which claims the benefit of U.S. Provisional Application Ser. No. 61/429,325, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jan. 3, 2011 and U.S. Provisional Application Ser. No. 61/502,067, entitled “METHOD FOR TREATING PHYTOPHOTODERMATITIS,” filed Jun. 28, 2011—all of which are hereby incorporated herein by reference in their entirety, including all references cited therein.1. Field of the InventionThe present invention relates in general to a method for treating ...

METHODS AND COMPOSITIONS FOR REDUCING EPIGENETIC AGE AND MITOCHONDRIAL DYSFUNCTION

Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells. 1. An antiaging composition for improving mitochondrial health of a subject , comprising a therapeutically effective dose of a mitochondrial biogenesis promoter and a therapeutically effective dose of a demethylase promoter.2. The antiaging composition as recited in claim 1 , further comprising a mitochondrial fusion promoter.3. The antiaging composition as recited in claim 2 , combined into a dose deliverable as powder claim 2 , liquid claim 2 , paste claim 2 , capsules claim 2 , caplets or tablets.4. The antiaging composition as recited in claim 1 , further comprising a mitochondrial fission promoter.5. The antiaging composition as recited in claim 4 , combined into a dose deliverable as powder claim 4 , liquid claim 4 , paste claim 4 , capsules claim 4 , caplets or tablets.6. The antiaging composition as recited in claim 1 , wherein claim 1 ,the biogenesis promoter comprises one or more selected from the group consisting of about 1 to about 100 mg of PQQ, about 5 to about 500 mg of methylene blue, and about 20 mg to about 5 g dihydromyricetin; andthe demethylase promoter comprises a combined dose of about 50 mg to about 50 g of one or more of the group consisting of alpha-ketoglutarate, ammonium alpha-ketoglutarate, arginine alpha-ketoglutarate, calcium alpha-ketoglutarate, creatine alpha-ketoglutarate, glutamine alpha-ketoglutarate, leucine alpha-ketoglutarate, lithium alpha-ketoglutarate, magnesium alpha-ketoglutarate, ornithine alpha-ketoglutarate, potassium alpha-ketoglutarate, sodium alpha-ketoglutarate, and taurine alpha-ketoglutarate.7. The antiaging composition as recited in claim 6 , further comprising a mitochondrial fusion promoter that comprises one or more selected from ...

MELANOMA CHEMOPREVENTION

Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi. 1. A method of reducing progression of atypical nevi in a subject , comprising administering orally to a subject having atypical nevi a therapeutically effective amount of a pharmaceutical composition comprising sulforaphane , thereby reducing progression of the atypical nevi.2. A method of preventing melanoma in a subject , comprising administering orally to a subject a therapeutically effective amount of a pharmaceutical composition comprising sulforaphane , thereby preventing melanoma in the subject.3. The method of claim 1 , wherein reducing progression comprises reducing emergence of additional atypical nevi in the subject.4. The method of claim 1 , wherein reducing progression comprises reducing transition of atypical nevi from morphologically less atypical to morphologically more atypical on a tiered scale.5. The method of claim 1 , comprising administering the sulforaphane as a tea or as a gel capsule.6. The method of claim 1 , comprising administering about 50 to about 400 μM of sulforaphane.7. The method of claim 1 , comprising administering about 0.5 to about 10 UM of sulforaphane per kilogram of bodyweight of the subject.8. The method of claim 1 , comprising administering about 50 claim 1 , about 100 claim 1 , or about 200 μM of sulforaphane.9. The method of claim 1 , comprising administering about 0.5 claim 1 , about 2.0 claim 1 , or about 4.0 μM of sulforaphane per kilogram of bodyweight of the subject.10. The method of claim 1 , comprising administering ...

METHODS AND MATERIALS FOR PROMOTING BONE FORMATION

This document provides methods and materials involved in promoting new bone formation for the treatment of medical conditions such as osteoporosis, bone defects, bone injury (e.g., fractures) implant ingrowth, and joint/spine fusions. For example, methods and materials for using sulforaphane and/or EZH2 polypeptide inhibitors (e.g., GSK126 or UNC1999) to treat osteoporosis, bone fractures and defects, implant ingrowth, and joint fusions are provided. 1. A method for reversing osteoporosis in a mammal , wherein the method comprises:(a) identifying a mammal as having osteoporosis, and(b) administering an inhibitor of an EZH2 polypeptide to the mammal, thereby reversing the osteoporosis.2. The method of claim 1 , wherein the mammal is a human.3. The method of claim 1 , wherein the inhibitor is selected from the group consisting of GSK126 claim 1 , UNC1999 claim 1 , EPZ005687 claim 1 , GSK343 claim 1 , EPZ-6438 claim 1 , and EI1.4. A method for preventing the onset of osteoporosis in a mammal at risk for developing osteoporosis claim 1 , wherein the method comprises:(a) identifying a mammal as being at risk for developing osteoporosis, and(b) administering an inhibitor of an EZH2 polypeptide to the mammal, thereby preventing the onset of osteoporosis.5. The method of claim 4 , wherein the mammal is a human.6. The method of claim 4 , wherein the inhibitor is selected from the group consisting of GSK126 claim 4 , UNC1999 claim 4 , EPZ005687 claim 4 , GSK343 claim 4 , EPZ-6438 claim 4 , and EI1.7. A method for treating a bone injury or bone defect in a mammal claim 4 , wherein the method comprises:(a) identifying a mammal as having a bone injury or defect, and(b) administering an inhibitor of an EZH2 polypeptide to the mammal, thereby enhancing bone healing and repair.8. The method of claim 7 , wherein the mammal is a human.9. The method of claim 7 , wherein the inhibitor is selected from the group consisting of GSK126 claim 7 , UNC1999 claim 7 , EPZ005687 claim 7 , GSK343 ...

COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The invention also relates to the combination of sulforaphane or a derivative thereof and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present invention also relates to the combination of a broccoli extract or powder and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present provides compositions and methods relating to these combinations. 121-. (canceled)22. An orally administrable composition comprising a broccoli extract or powder and a mushroom extract or powder.23. The orally administrable composition of claim 22 , wherein the broccoli extract or powder comprises glucoraphanin in an amount of about 1 to about 75% w/w.24. The orally administrable composition of claim 22 , wherein the broccoli extract or powder comprises myrosinase.25. The orally administrable composition of claim 22 , further comprising an enzyme potentiator.26. The orally administration composition of claim 22 , wherein the enzyme potentiator comprises ascorbic acid.27. The orally administrable composition of claim 22 , wherein the composition comprises an enteric dosage form.28. The orally administrable composition of claim 22 , wherein the mushroom extract or powder comprises one or more mushroom extracts or powders selected from the group of: maitake mushroom extract claim 22 , shiitake mushroom extract claim 22 , and reishi mushroom extract.29. The orally administrable composition of claim 22 , comprising a maitake mushroom extract comprising one or more glucans.30. The orally administrable composition of claim 22 , comprising a maitake mushroom extract comprising beta-glucan.31. The orally administrable composition of claim 22 , comprising a shiitake mushroom ...

Method for treating bladder cancer

A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

METHOD FOR ENHANCING THE SECRETION OF GLP-1 USING BITTER COMPOUNDS

The present invention provides a method for enhancing the secretion of GLP-1 of the intestinal endocrine L-cells using a bitter compound, wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate. The bitter compound can regulate the secretion of GLP-1, thus is potentially reliable for the development of medicament or healthy victual. 1. A method for enhancing the secretion of GLP-1 of the intestinal endocrine cell using a bitter compound , wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate.4. The method according to claim 2 , wherein R is the chain of glucose (glucose)and n is 0 or any integral number from 1 to 7.5. The method according to claim 2 , wherein R is the chain of allose (allose)and n is 0 or any integral number from 1 to 7.6Momordica charantia.. The method according to claim 2 , wherein the bitter compound is from9Momordica charantia.. The method according to claim 7 , wherein the bitter compound is from10. The method according to claim 1 , wherein the intestinal endocrine cell is proglucagon-expression cell line STC-1.11. The method according to claim 1 , wherein the allyl isothiocyanate enhances the secretion of GLP-1 through stimulating a bitter taste receptor TAS2R38.12. A pharmaceutical composition for enhancing the secretion of GLP-1 of the intestinal endocrine cell claim 1 , comprising a pharmaceutically acceptable carrier and an effective amount of the bitter compound according to .13. The pharmaceutical composition according to claim 12 , wherein the bitter compound is a cucurbitane-triterpenoid.14. The pharmaceutical composition according to claim 12 , wherein the bitter compound is allyl isothiocyanate.15. The pharmaceutical composition according to claim 14 , wherein the allyl isothiocyanate enhances the secretion of GLP-1 through stimulating a bitter taste receptor TAS2R38. This application claims priority to Taiwan Patent Application No. 102105095 filed on 8 Feb. 2013. All disclosure ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The pharmaceutical composition of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris COR claim 1 , lower alkyl substituted by —CO(lower alkyl) claim 1 , lower alkyl substituted with —CO(lower alkoxyalkyl) claim 1 , lower alkoxyalkyl substituted with —CO(lower alkyl) claim 1 , or lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl).3. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , and Ris H.4. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , Ris COR claim 2 , and -d-Rand -e-Rare not both —O-(lower alkyl) or —O-(lower alkoxyalkyl).5. The pharmaceutical composition of claim 1 , wherein{'sub': '17', '(a) Ris lower alkyl;'}{'sub': 18', '2', '10, '(b) Ris CN or COR;'}{'sub': 11', '12', '13, 'claim-text': (i) —O-(lower alkyl);', {'sub': '2', '(ii) —O-(lower alkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(iii) —O-(lower alkyl substituted with —CO(lower alkoxyalkyl));'}, '(iv) —O-(lower alkyl substituted with fluorine or chlorine);', '(v) —O-(lower alkoxyalkyl);', {'sub': '2', '(vi) —O-(lower alkoxyalkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(vii) —O-(lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl));'}, '(viii) —O-(lower alkyl substituted with fluorine or chlorine); or', {'sub': 2', '10, '(ix) -(single bond)-COR; and'}], '(c) at least one ...

METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA)

The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): 2. The method of claim 1 , wherein Ris an isothiocyanate.3. The method of claim 2 , wherein the compound is sec-butyl isothiocyanate or ethyl isothiocyanate.4. The method of claim 2 , wherein n′ is 0.5. The method of claim 4 , wherein the compound is at least one of benzoyl isothiocyanate claim 4 , 4-bromophenyl isothiocyanate claim 4 , 4-(methylthio)phenyl isothiocyanate claim 4 , 1-naphthyl isothiocyanate claim 4 , 3-methoxyphenyl isothiocyanate claim 4 , and 4-methoxyphenyl isothiocyanate.6. The method of claim 2 , wherein n′ is at least 1.7. The method of claim 6 , wherein the compound is at least one of benzyl isothiocyanate claim 6 , 3-diethylaminopropyl isothiocyanate claim 6 , N-Boc-4-isothiocyanatobutylamine claim 6 , 3-(4-morpholino)propyl isothiocyanate claim 6 , 2-(4-morpholino)ethyl isothiocyanate claim 6 , or 2-piperidinoethyl isothiocyanate.8. The method of further comprising contacting the bacterium with a second agent selected from the group consisting of Omega 3 oil claim 1 , salicylic acid claim 1 , dimethylbutanol claim 1 , garlic oil claim 1 , olive oil claim 1 , krill oil claim 1 , Co enzyme Q-10 claim 1 , a probiotic claim 1 , a prebiotic claim 1 , dietary fiber claim 1 , psyllium husk claim 1 , bismuth salts claim 1 , phytosterols claim 1 , grape seed oil claim 1 , green tea extract claim 1 , vitamin D claim 1 , an antioxidant claim 1 , turmeric claim 1 , curcumin claim 1 , resveratrol claim 1 , activated charcoal claim 1 , and copper chlorophyllin.9. The method of claim 1 , wherein conversion of choline to trimethylamine (TMA) is inhibited by from about 1% to about 100%.10Proteus mirabilis, Desulfovibrio alaskensis, Clostridium ljungdahlii, C. scindens, C. aldenense, Collinsella tanakaei, ...

METHODS AND COMPOSITIONS FOR REDUCING EPIGENETIC AGE AND MITOCHONDRIAL DYSFUNCTION

Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells. 2. The method as recited in claim 1 , wherein step (a) comprises administering to the subject one or more selected from the group consisting of about 100 mg to about 20 g of a bioavailable stearic acid source claim 1 , about 5 mg to about 5 g of a bioavailable sulforaphane source claim 1 , and about 20 mg to about 5 g dihydromyricetin.3. The method as recited in claim 1 , wherein step (b) comprises administering a mitochondrial UCP2 blocker.4. The method as recited in claim 1 , wherein step (b) comprises administering about 0.1 mg to about 50 mg of a fullerene dissolved in a biocompatible solvent.5. The method as recited in claim 4 , wherein the fullerene is substantially C60.6. The method as recited in claim 1 , wherein step (c) comprises administering about 50 mg to about 50 g of one or more selected from the group consisting of alpha-ketoglutarate claim 1 , ammonium alpha-ketoglutarate claim 1 , arginine alpha-ketoglutarate claim 1 , calcium alpha-ketoglutarate claim 1 , creatine alpha-ketoglutarate claim 1 , glutamine alpha-ketoglutarate claim 1 , leucine alpha-ketoglutarate claim 1 , lithium alpha-ketoglutarate claim 1 , magnesium alpha-ketoglutarate claim 1 , ornithine alpha-ketoglutarate claim 1 , potassium alpha-ketoglutarate claim 1 , sodium alpha-ketoglutarate claim 1 , and taurine alpha-ketoglutarate.7. The method as recited in claim 1 , further comprising:(d) promoting cell signaling.8. A method for reducing epigenetic age in a subject having stem cells with mitochondria claim 1 , comprising administering to the subject:a mitochondrial fusion promoter comprising one or more selected from the group consisting of about 100 mg to about 20 g of a bioavailable stearic acid source, ...

CHALLENGE TEST FOR DIAGNOSING A SUBTYPE OF AUTISM SPECTRUM DISEASE

The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and wherein an ASD phenotype 1 patient is identified by a negative response. 2. (canceled)4. The method according to claim 2 , wherein the Nrf2-activator is administered for 1 claim 2 , 2 claim 2 , 3 claim 2 , 4 or 5 days.5. The method according to claim 2 , wherein the Nrf2-activator is administered at a dosage level of at least 2 μmol/kg.6. The method according to claim 2 , wherein a negative response comprises one or more selected from an increase in scores of ABC-I claim 2 , SRS claim 2 , ADOS raw domain and SS claim 2 , increased latency or impossibility to respond to eye contact claim 2 , diminished initiation of speech measured by mean number of verbal initiation within a given time interval in a similar contextual environment claim 2 , increased latency to response to verbal initiation claim 2 , decrease in executive functioning claim 2 , decreased ability to plan and implement multiple step tasks claim 2 , decrease in behavioral compliance claim 2 , increased irritability claim 2 , heightened sensitivity to sensory stimuli claim 2 , decrease in short term memory retention and marked increase of idiosyncratic behaviors and postures.7. The method according to claim 2 , wherein the Nrf2-activator is one selected from the group ...

USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES

The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers. 1. A method to ameliorate the mechanical resilience of skin in a patient in need thereof comprising administering to the patient a composition comprising a therapeutically effective amount of an Nrf2 inducer.2. The method of claim 1 , wherein the patient suffers from skin blistering.3. The method of claim 1 , wherein the Nrf2 inducer is a phase II enzyme inducer.4. The method of claim 3 , wherein the phase II inducer is an isothiocyanate.5. The method of claim 4 , wherein the phase II enzyme inducer is sulforaphane.6. The method of claim 4 , wherein the phase II enzyme inducer is a sulforaphane synthetic analogue.7. The method of claim 6 , wherein the sulforaphane synthetic analogue is exo-2-acetyl-6-isothiocyanatonorbomane.8. The method of claim 1 , wherein the Nrf2 inducer is keratinocyte growth factor.9. The method of claim 1 , wherein the Nrf2 inducer is oltipraz.10. The method of claim 1 , wherein the Nrf2 inducer is ethacrynic acid.11. The method of claim 1 , wherein the Nrf2 inducer causes the selective induction of K6 claim 1 , K16 or K17 in the keratinocytes in the skin of the patient.12. The method of claim 1 , wherein the composition comprising the Nrf2 inducer is topically administered to the patient.13. The method of claim 12 , wherein the amount of Nrf2 inducer in the composition topically administered to the patient is from about 100 nmol to about 1 μmol/cm.14. The method of claim 12 , wherein the composition comprising the Nrf2 inducer is a topical preparation selected from the group consisting of ointment claim 12 , cream claim 12 , emulsion claim 12 , lotion and gel.15. The method of claim 13 , wherein the composition father comprises one or more pharmaceutical ...

METHOD FOR TREATING NEURODEGENERATIVE DISEASES

A method for treating neurodegenerative diseases including the step of administering an isothiocyanate functional surfactant to an area affected by a neurodegenerative disease, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 1. A method for treating a neurodegenerative disease , comprising the step(s) of:administering an isothiocyanate functional surfactant to an area affected by a neurodegenerative disease, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.2. The method for treating the neurodegenerative disease according to claim 1 , further comprising the step of removing the isothiocyanate functional surfactant from the area affected by the neurodegenerative disease after a period of time.3. A method for treating a neurodegenerative disease claim 1 , comprising the steps of:administering an isothiocyanate functional surfactant to an area affected by a neurodegenerative disease, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant;removing the isothiocyanate functional surfactant from the area affected by the neurodegenerative disease after a period of time; andrepeating the steps of administering and removing the isothiocyanate functional surfactant to/from the affected area.4. A method for treating a neurodegenerative disease claim 1 , comprising the steps of:associating an area affected by a neurodegenerative disease with an isothiocyanate functional surfactant, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or ...

Method for Treating Skin Cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 112-. (canceled)14. The method for treating skin cancer according to claim 13 , further comprising the step of administering an additional surfactant claim 13 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 13 , an anionic surfactant claim 13 , a cationic surfactant claim 13 , a zwitterionic surfactant claim 13 , and combinations thereof.15. The method for treating skin cancer according to claim 13 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma claim 13 , squamous cell carcinoma claim 13 , melanoma claim 13 , and merkel cell carcinoma.17. The method for treating skin cancer according to claim 16 , further comprising the step of administering an additional surfactant claim 16 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 16 , an anionic surfactant claim 16 , a cationic surfactant claim 16 , a zwitterionic surfactant claim 16 , and combinations thereof.18. The method for treating skin cancer according to claim 16 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma claim 16 , squamous cell carcinoma claim 16 , melanoma claim 16 , and merkel cell carcinoma.20. The method for treating skin cancer according to claim 19 , further comprising the step of administering an additional surfactant claim 19 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 19 , an anionic surfactant claim 19 , a cationic surfactant claim 19 , a zwitterionic ...

METHOD FOR TREATING METASTATIC PROSTATE CANCER

A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 117-. (canceled)18. A method for treating metastatic prostate cancer , comprising the step of:administering an isothiocyanate functional compound to a patient having metastatic prostate cancer.19. The method according to claim 18 , wherein the isothiocyanate functional compound comprises an α-nitrogen and a ε-nitrogen claim 18 , and wherein an alkyl and/or alkanoyl substituent comprising at least 8 carbon atoms is bound to the α-nitrogen claim 18 , and further wherein the ε-nitrogen forms part of the isothiocyanate functional group wherein said isothiocyanate functional compound comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional compound.20. The method according to claim 18 , wherein the isothiocyanate functional compound comprises a lysine derivative claim 18 , wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen claim 18 , and wherein an alkanoyl substituent comprising 8 carbon atoms is bound to the α-nitrogen claim 18 , and further wherein the ε-nitrogen forms part of an isothiocyanate functional group.29. The method according to claim 18 , wherein the isothiocyanate functional compound is administered to the patient at least one of orally claim 18 , intravenously claim 18 , intramuscularly claim 18 , intrathecally claim 18 , cutaneously claim 18 , subcutaneously claim 18 , transdermally claim 18 , sublingually claim 18 , buccally claim 18 , rectally claim 18 , and nasally.30. The method according to claim 29 , wherein the amount of isothiocyanate ...

METHOD FOR TREATING RHEUMATOID ARTHRITIS

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an sothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 117-. (canceled)18. A method for treating rheumatoid arthritis , comprising the step of:administering an isothiocyanate functional compound to an area affected by rheumatoid arthritis.19. The method according to claim 18 , wherein the isothiocyanate functional compound comprises an α-nitrogen and a ε-nitrogen claim 18 , and wherein an alkyl and/or alkanoyl substituent comprising at least 8 carbon atoms is bound to the α-nitrogen claim 18 , and further wherein the ε-nitrogen forms part of the isothiocyanate functional group wherein said isothiocyanate functional compound comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional compound.20. The method according to claim 18 , wherein the isothiocyanate functional compound comprises a lysine derivative claim 18 , wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen claim 18 , and wherein an alkanoyl substituent comprising 8 carbon atoms is bound to the α-nitrogen claim 18 , and further wherein the ε-nitrogen forms part of an isothiocyanate functional group.29. The method according to claim 18 , wherein the isothiocyanate functional compound is administered to the patient at least one of orally claim 18 , intravenously claim 18 , intramuscularly claim 18 , intrathecally claim 18 , cutaneously claim 18 , subcutaneously claim 18 , transdermally claim 18 , sublingually claim 18 , buccally claim 18 , rectally claim 18 , topically claim 18 , and nasally.30. The method ...

METHOD OF TREATING OR PREVENTING TUMORS USING 1-(ALKYLSULFINYL)-2-ISOTHIOCYANATOALKYL-1-ALKENE

A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene. 2. The method of claim 1 , wherein Rand Rboth are hydrogen.3. The method of claim 1 , wherein Ris a methylene and n=2.4. The method of claim 1 , wherein the formula I is sulforaphene with a chemical name of 4-isothiocyanato-1-(methylsulfinyl)-1-butene.5. The method of claim 4 , wherein sulforaphene is extracted from radish seeds claim 4 , radish seedlings claim 4 , or radish.6. The method of claim 1 , wherein the pharmaceutical composition claim 1 , health product claim 1 , and food additive comprise a pharmaceutically acceptable carrier claim 1 , an additive claim 1 , and a pharmaceutically acceptable excipient.7. The method of claim 4 , wherein the pharmaceutical composition claim 4 , health product claim 4 , and food additive comprise a pharmaceutically acceptable carrier claim 4 , an additive claim 4 , and a pharmaceutically acceptable excipient. This application is a continuation-in-part of International Patent Application No. PCT/CN2013/084832 with an international filing date of Oct. 8, 2013, designating the United States, now pending, the contents of which, including any intervening amendments thereto, are incorporated herein by reference. Inquiries from the public to applicants or assignees concerning this document or the related applications should be directed to: Matthias Scholl P.C., Attn.: Dr. Matthias Scholl Esq., 245 First Street, 18th Floor, and Cambridge, Mass. 02142.1. Field of the InventionThe invention relates to use of 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene for treating or preventing human or mammalian cancers and tumors.2. Description of the Related ArtThe antitumor activity of 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene has not been reported heretofore.Unexpectedly, ...

METHODS OF TREATING AND PREVENTING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X, P2X, P2Y, and P2Yreceptors. Examples of disease or disorder of the CNS include brain injury, particularly traumatic brain injury, inflammation, infection, degeneration of brain cells, stroke, brain edema, tumor, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Also disclosed is a kit comprising at least one anti-inflammatory agent and printed materials containing instructions for transcranially administering the anti-inflammatory agent to the patient having a disease or disorder of the CNS. 130.-. (canceled)31. A method of treating or preventing a disease or disorder of the central nervous system (CNS) selected from the group consisting of brain injury , infection , degeneration of brain cells , brain edema , Alzheimer's disease , Parkinson's disease , and multiple sclerosis in a patient comprising administering transcranially an effective amount of an anti-inflammatory agent to the patient , wherein the anti-inflammatory agent is selected from the group consisting of anti-oxidants , purinergic receptor inhibitors , and connexin hemichannel inhibitors.32. The method of claim 31 , wherein the treating or preventing comprises inhibiting claim 31 , reducing claim 31 , or eliminating (a) the formation of reactive microglia claim 31 , (b) the recruitment of neutrophils and/or monocytes claim 31 , or (c) reducing the number of dead cells in the brain parenchyma or meninges in the patient.33. The method of claim 31 , wherein the anti-inflammatory agent is an anti-oxidant selected from the group consisting of glutathione claim 31 , ascorbic acid claim 31 , lipoic acid claim 31 , uric acid ...

Method for treating benign prostatic hyperplasia (bph), prostatitis, and prostate cancer

A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

Inhibitors of macrophage migration inhibitory factor

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 120-. (canceled)21. A method for treating an infectious disease , comprising the step of:administering an isothiocyanate functional compound to an area affected by an infectious disease.22. The method according to claim 21 , wherein the infectious disease comprises at least one of a bacterial infection claim 21 , a fungal infection claim 21 , a prion infection claim 21 , a protozoan infection claim 21 , and a viral infection.23. The method according to claim 22 , wherein the bacterial infection comprises at least one of actinomycosis claim 22 , anthrax claim 22 , bejel claim 22 , boutonneuse fever claim 22 , brucellosis claim 22 , brucellosis spondylitis claim 22 , bubonic plague claim 22 , campylobacteriosis claim 22 , carrión disease claim 22 , cat scratch disease claim 22 , cervicitis claim 22 , chancroid claim 22 , chlamydia claim 22 , lymphogranuloma venereum claim 22 , cholera claim 22 , clostridial infection claim 22 , dysentery claim 22 , shigellosis claim 22 , epididymitis claim 22 , erysipelothrix infection claim 22 , glanders claim 22 , gonorrhea claim 22 , granuloma inguinale claim 22 , gumma claim 22 , legionnaire disease claim 22 , leprosy claim 22 , leptospirosis claim 22 , listeriosis claim 22 , lyme disease claim 22 , melioidosis claim 22 , methicillin-resistant Staphylococcus aureus claim 22 , nocardiosis claim 22 , paratyphoid fever claim 22 , pharyngitis claim 22 , plague claim 22 , pneumonia claim 22 , proctitis claim 22 , pseudotuberculosis claim 22 , psittacosis claim 22 , q-fever claim 22 , rat-bite fever claim 22 , Reiter syndrome claim 22 , relapsing fever claim 22 , rheumatic fever claim 22 , Rocky Mountain spotted fever claim 22 , salmonellosis ...

FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES

Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α, β unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. (canceled)27. (canceled)28. A suspension pharmaceutical composition for administration for reducing toxic effects of ionizing radiation in a subject , comprising an effective amount of at least one radioprotective α , β unsaturated aryl sulfone and at least one hydrophilic wetting agent having an HLB value between about 6 and about 17 in an amount between about 0.1% w/v and about 5% w/v , an agent to effect isotonicity; and , wherein the composition exhibits a pH between about 7.5 and about 9.5.29. The pharmaceutical composition according to comprising between about 20 mg/ml to about 150 mg/ml of at least one radioprotective α claim 28 , β unsaturated aryl sulfone and at least one hydrophilic wetting agent in an amount between about 0.5% w/v and about 2.5% w/v selected from the group consisting of Sorbitan monopalmitate (Span 40) claim 28 , Sorbitan monolaurate (Span 20) claim 28 , Polyoxyethylene sorbitan tristearate claim 28 , (Tween 65) claim 28 , Polyoxyethylene sorbitan trioleate claim 28 , (Tween 85) claim 28 , Polyethylene glycol 400 claim 28 , Polysorbate 60 claim 28 , NF claim 28 , (Tween 60) claim 28 , Polyoxyethylene monostearate claim 28 , Polysorbate 80 claim 28 , NF claim 28 , (Tween 80) claim 28 , Polysorbate 40 claim 28 , NF claim 28 , (Tween 40) claim 28 , Polysorbate 20 ...

FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS

A field of biological fungicides with a broad range of antifungal activity coming from plant extracts from the order of Brassicales or molecules revealing similar chemical structure. In particular, Applicants surprisingly provided a new usage of a combination of sulfonyl and sulfinyl containing aliphatic glucosinolates, their by-products and synthetic analogues as efficient antifungal compounds with broad spectrum of activity. 1. A method for the prevention or treatment of fungal pathogens in plants comprising treating the plants with a composition comprising the combination of at least two compounds selected from the group consisting of:1-Isothiocyanato-8-(methylsulfinyl)-octane/1-Isothiocyanato-8-(methylsulfonyl)-octane; 1-(isothiocyanatomethyl)-3-(4-(methylsulfinyl)butyl)benzene/1-(isothiocyanatomethyl)-3-(4-(methylsulfonyl)butyl)benzene; 1-(ethylsulfinyl)-8-isothiocyanatooctane/1-(ethylsulfonyl)-8-isothiocyanatooctane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-3-(methylsulfonyl)-propane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-7-(methylsulfinyl)-heptane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-3-(methylsulfinyl)-propane; 1-Isothiocyanato-8-(methylsulfonyl)-octane/1-Isothiocyanato-6-(methylsulfinyl)-hexane; 1-Isothiocyanato-8-(methylsulfinyl)-octane/1-Isothiocyanato-3-(methylsulfonyl)-propane; 1-Isothiocyanato-8-(methylsulfinyl)-octane/1-Isothiocyanato-7-(methylsulfinyl)-heptane; 1-Isothiocyanato-8-(methylsulfinyl)-octane/1-Isothiocyanato-6-(methylsulfinyl)-hexane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-8-(methylsulfinyl)-octane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-3-(methylsulfonyl)-propane; 1-Isothiocyanato-8-(methylsulfinyl)-octane/1-Isothiocyanato-9-(methylsulfonyl)-nonane; (E)-1-isothiocyanato-8-(methylsulfinyl)oct-2-ene/1-Isothiocyanato-7-(methylsulfinyl)-heptane; 1-(ethylsulfinyl)-8-isothiocyanatooctane/1-Isothiocyanato-7-( ...

Method for Treating Skin Cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 112-. (canceled).14. The method for treating skin cancer claim 13 , according to claim 13 , further comprising the step of applying an additional surfactant claim 13 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 13 , an anionic surfactant claim 13 , a cationic surfactant claim 13 , a zwitterionic surfactant claim 13 , and combinations thereof.15. The method for treating skin cancer claim 13 , according to claim 13 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma claim 13 , squamous cell carcinoma claim 13 , melanoma claim 13 , and merkel cell carcinoma.17. The method for treating skin cancer claim 16 , according to claim 16 , further comprising the step of applying an additional surfactant claim 16 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 16 , an anionic surfactant claim 16 , a cationic surfactant claim 16 , a zwitterionic surfactant claim 16 , and combinations thereof.18. The method for treating skin cancer claim 16 , according to claim 16 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma claim 16 , squamous cell carcinoma claim 16 , melanoma claim 16 , and merkel cell carcinoma.20. The method for treating skin cancer claim 19 , according to claim 19 , further comprising the step of applying an additional surfactant claim 19 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 19 , an anionic surfactant claim 19 , a cationic ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The pharmaceutical composition of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris COR claim 1 , lower alkyl substituted by —CO(lower alkyl) claim 1 , lower alkyl substituted with —CO(lower alkoxyalkyl) claim 1 , lower alkoxyalkyl substituted with —CO(lower alkyl) claim 1 , or lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl).3. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , and Ris H.4. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , Ris COR claim 2 , and -d-Rand -e-Rare not both —O-(lower alkyl) or —O-(lower alkoxyalkyl).5. The pharmaceutical composition of claim 1 , wherein{'sub': '17', '(a) Ris lower alkyl;'}{'sub': 18', '2', '10, '(b) Ris CN or COR;'}{'sub': 11', '12', '13, 'claim-text': (i) —O-(lower alkyl);', {'sub': '2', '(ii) —O-(lower alkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(iii) —O-(lower alkyl substituted with —CO(lower alkoxyalkyl));'}, '(iv) —O-(lower alkyl substituted with fluorine or chlorine);', '(v) —O-(lower alkoxyalkyl);', {'sub': '2', '(vi) —O-(lower alkoxyalkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(vii) —O-(lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl));'}, '(viii) —O-(lower alkyl substituted with fluorine or chlorine); or', {'sub': 2', '10, '(ix) -(single bond)-COR; and'}], '(c) at least one ...

Method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene

A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene.

COMPOSITIONS FOR THE TREATMENT OF DRY EYE AND METHODS OF USE THEREOF

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye. 1. A composition for stimulating tearing when orally administered to a subject , the composition comprising: a core comprising water and an amount of allyl isothiocyanate effective for stimulating tearing , and a shell encapsulating the core.2. The composition of claim 1 , wherein the core comprises a hydrated wasabi paste.3. The composition of claim 1 , wherein the shell is water-resistant.4. The composition of claim 1 , wherein the shell comprises hypromellose.5. The composition of claim 1 , wherein the shell comprises one or more layers of a hard candy shell comprising sugar.6. The composition of claim 4 , wherein the shell is encapsulated in a second shell that is a hard candy shell comprising sugar.7. The composition of claim 1 , wherein the core further comprises a flavoring agent.8. The composition of claim 7 , wherein the flavoring agent is menthol or a menthol-containing oil.9. The composition of claim 5 , wherein the hard candy shell further comprises a flavoring agent.10. The composition of claim 1 , wherein the core stimulates tearing that therapeutically treats one or more symptoms of dry eye in the subject.11. The composition of claim 1 , wherein the core stimulates an increase in tear production by over 10 mm in the subject claim 1 , as measured on a Schirmer's test.12. A method of manufacturing a composition for stimulating tearing when orally administered by a subject claim 1 , comprising the steps of:(a) providing a core comprising water and an amount of allyl isothiocyanate effective for stimulating tearing; and(b) encapsulating the core in a shell.13. The method of claim 12 , wherein the core comprises a hydrated wasabi paste.14. The method of claim 12 , wherein the shell comprises hypromellose.15. The method of claim 12 , wherein the shell comprises one or more layers of a hard candy shell ...

NUTRITIONAL SUPPLEMENT AND PROCESS OF PREPARATION

Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with at least one strain of to form a mixture, causing the mixture to undergo lactic fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane, and then producing from the fermented mixture a supplement that can be ingested by an individual. 1. A process for producing a sulforaphane-containing nutritional supplement , the process comprising:{'i': 'Lactobacillus', 'combining a cruciferous vegetable with at least one strain of to form a mixture;'}causing the mixture to undergo lactic fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane; andproducing from the fermented mixture a supplement that can be ingested by an individual.2. The process according to claim 1 , wherein the cruciferous vegetable is broccoli sprouts.3. The process according to claim 2 , further comprising adding at least a second cruciferous vegetable other than broccoli sprouts to the mixture prior to the lactic fermentation thereof.4LactobacillusB. bifidum, B. lactis, B. infantis, B. longum, L. acidophilus, L. brevis, L. bulgaricus, L. paracasei, L. plantarum, L. rhamnosus, L. salivaricusStreptococcus thermophilus.. The process according to claim 1 , wherein the at least one strain of is more than one of claim 1 , and5LactobacilliB. bifidum, B. lactis, B. infantis, B. longum, L. acidophilus, L. brevis, L. bulgaricus, L. paracasei, L. plantarum, L. rhamnosus, L. salivaricusStreptococcus thermophilus.. The process according to claim 1 , wherein the at least one comprises each of claim 1 , and6. The process according to claim 1 , wherein the mixture has an acidic pH during the lactic fermentation of the mixture.7. The process ...

DIETARY AND NATURAL PRODUCT MANAGEMENT OF NEGATIVE SIDE EFFECTS OF CANCER TREATMENT

The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN). The invention provides that administering a composition comprising curcumin, EGCG, sulforaphane, alone or combined with a ketogenic diet or a modified ketogenic diet (low carbohydrate diet) alone or supplemented with MCT improves resistance of normal cells to cytotoxicity of cancer treatments, in turn, reducing their negative side effects. Increasing normal cells, tissues or organs' resistance to chemotherapeutic agents, the invention improves patients' tolerance to anti-cancer treatments' toxicity, which, in turn, contributes to enhance their efficacy, leading to increased survival of the subject treated with the current invention. 1. A method for controlling , managing , delaying , inhibiting or reversing the negative side effects of cancer treatments2. The method of comprises administering an effective amount of a compound or compounds selected from the group consisting of epigallocatechin-3-gallate claim 1 , curcumin claim 1 , and a composition comprising glucosinolates and/or derivatives thereof claim 1 , such as sulforaphane (SFN) claim 1 , and claim 1 , optionally claim 1 , providing to the subject a ketogenic diet or a modified ketogenic diet alone or supplemented with medium chain triglycerides.3. The method of - wherein said ...

Sulforaphane for Treating or Reducing Insulin Resistance of the Liver

The present invention provides sulforaphane, or a plant extract comprising sulforaphane, for treating or reducing insulin resistance of the liver. Especially, there is provided sulforaphane, or a plant extract comprising sulforaphane, for treating or reducing insulin resistance of the liver, wherein, in the subject to be treated, the insulin resistance index of the liver is higher than the insulin resistance of other metabolic tissue. 1. A method of treating or reducing insulin resistance of the liver and/or improving hepatic insulin sensitivity , the method comprising the step of administering an effective amount of sulforaphane , or a plant extract comprising an effective amount of sulforaphane , to a mammal in need thereof.2. The method according to claim 1 , wherein said method improves glucose tolerance.3. The method according to any claim 1 , wherein sulforaphane claim 1 , or the plant extract comprising sulforaphane claim 1 , is administrated by injection or orally.4. The method according to claim 1 , wherein the effective amount of sulforaphane comprises a daily administered dose of sulforaphane ranging from 10 to 1000 μmole.5. The method according to claim 1 , wherein the effective amount of sulforaphane administered to said mammal is a daily administered dose ranging from 1 to 100 mg/kg of the mammal's body weight.6. The method according to claim 1 , wherein claim 1 , the mammal to be treated claim 1 , has an insulin resistance index of the liver that is higher than the insulin resistance index of other metabolic tissue.7. The method according to claim 1 , wherein claim 1 , in the mammal to be treated claim 1 , the insulin resistance index of the liver is higher than the insulin resistance index of body fat or muscles.8. The method according to claim 1 , wherein claim 1 , in the mammal to be treated claim 1 , the insulin resistance of metabolic tissue other than the liver is not is increased.9. The method according to claim 1 , wherein claim 1 , in the ...

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS

The present invention relates to a pharmaceutical composition for preventing or treating pulmonary fibrosis comprising an isothiocyanate-based compound and a biguanide agent as active ingredients, a method for preventing or treating pulmonary fibrosis using the composition, and use of the isothiocyanate-based compound and the biguanide agent for the preparation of the prophylactic or therapeutic agent for preventing or treating pulmonary fibrosis. The pharmaceutical composition comprising the isothiocyanate-based compound and the biguanide agent as active ingredients of the present invention can be used to stably prevent or treat pulmonary fibrosis for which specific therapeutic agents have not yet been known, and thus it can be widely used for health and welfare improvement through treatment of pulmonary fibrosis. 17-. (canceled)8. A method for treating pulmonary fibrosis , comprising the step of:(a) administering a pharmaceutical composition for treating pulmonary fibrosis comprising an isothiocyanate-based compound and a biguanide agent as active ingredients to a subject who has pulmonary fibrosis; or(b) administering a pharmaceutical composition comprising the isothiocyanate-based compound and a pharmaceutical composition comprising the biguanide agent sequentially or in reverse order or simultaneously to a subject who is suspected of having pulmonary fibrosis or has pulmonary fibrosis.9. The method according to claim 8 , wherein the composition comprising the isothiocyanate-based compound and the composition comprising the biguanide agent are administered at the same time.10. The method according to claim 8 , wherein the isothiocyanate-based compound is sulforaphane.11. The method according to claim 8 , wherein the biguanide agent is metformin.12. The method according to claim 8 , wherein the administration dose of the pharmaceutical composition comprising the isothiocyanate-based compound and the biguanide agent is approximately 1 μg/kg/day to 100 mg/kg/day.13 ...

MELANOMA CHEMOPREVENTION

Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi. 1. A method of preventing progression of atypical nevi in a subject , comprising administering orally to a subject having atypical nevi a therapeutically effective amount of a pharmaceutical composition comprising sulforaphane , thereby reducing progression of the atypical nevi.2. A method of preventing melanoma in a subject , comprising administering orally to a subject a therapeutically effective amount of a pharmaceutical composition comprising sulforaphane , thereby preventing melanoma in the subject.3. The method of claim 1 , wherein preventing progression comprises preventing emergence of additional atypical nevi in the subject.4. The method of claim 1 , wherein preventing progression comprises preventing transition of atypical nevi from morphologically less atypical to morphologically more atypical on a tiered scale.5. The method of claim 1 , comprising administering the sulforaphane as a tea or as a gel capsule.6. The method of claim 1 , comprising administering about 50 to about 400 μM of sulforaphane.7. The method of claim 1 , comprising administering about 0.5 to about 10 μM of sulforaphane per kilogram of bodyweight of the subject.8. The method of claim 1 , comprising administering about 50 claim 1 , about 100 claim 1 , or about 200 μM of sulforaphane.9. The method of claim 1 , comprising administering about 0.5 claim 1 , about 2.0 claim 1 , or about 4.0 μM of sulforaphane per kilogram of bodyweight of the subject.10. The method of claim 1 , comprising ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 2. The pharmaceutical composition of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris COR claim 1 , lower alkyl substituted by —CO(lower alkyl) claim 1 , lower alkyl substituted with —CO(lower alkoxyalkyl) claim 1 , lower alkoxyalkyl substituted with —CO(lower alkyl) claim 1 , or lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl).3. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , and Ris H.4. The pharmaceutical composition of claim 2 , wherein Ris H claim 2 , g is a single bond claim 2 , Ris COR claim 2 , and -d-Rand -e-Rare not both —O-(lower alkyl) or —O-(lower alkoxyalkyl).5. The pharmaceutical composition of claim 1 , wherein{'sub': '17', '(a) Ris lower alkyl;'}{'sub': 18', '2', '10, '(b) Ris CN or COR;'}{'sub': 11', '12', '13, 'claim-text': (i) —O-(lower alkyl);', {'sub': '2', '(ii) —O-(lower alkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(iii) —O-(lower alkyl substituted with —CO(lower alkoxyalkyl));'}, '(iv) —O-(lower alkyl substituted with fluorine or chlorine);', '(v) —O-(lower alkoxyalkyl);', {'sub': '2', '(vi) —O-(lower alkoxyalkyl substituted with —CO(lower alkyl));'}, {'sub': '2', '(vii) —O-(lower alkoxyalkyl substituted with —CO(lower alkoxyalkyl));'}, '(viii) —O-(lower alkyl substituted with fluorine or chlorine); or', {'sub': 2', '10, '(ix) -(single bond)-COR; and'}], '(c) at least one ...

METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION

This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided. 1. A method for identifying a mammal as having lung adenocarcinoma characterized by neuroendocrine differentiation , wherein said method comprises determining whether or not cancer cells from said mammal contain an elevated level of ASCL1 expression and an elevated level of RET expression , wherein the presence of said elevated level of ASCL1 expression and the presence of said elevated level of RET expression indicates that said mammal has lung adenocarcinoma characterized by neuroendocrine differentiation , and wherein the absence of said elevated level of ASCL1 expression and the absence of said elevated level of RET expression indicates that said mammal does not have lung adenocarcinoma characterized by neuroendocrine differentiation.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein said elevated level is determined using PCR.4. The method of claim 1 , wherein said elevated level is determined using immunohistochemistry.5. A method for identifying a mammal as having lung adenocarcinoma characterized by neuroendocrine differentiation claim 1 , wherein said method comprises:(a) determining whether or not a lung cancer cells from said mammal contain an elevated level of ASCL1 expression and an elevated level of RET expression,(b) classifying said mammal as having lung adenocarcinoma characterized by neuroendocrine differentiation if said sample contains said elevated level of ASCL1 expression and said elevated level of RET expression, and(c) ...

INHIBITOR OF MUSCLE DAMAGE OR MUSCLE FATIGUE

The present invention relates to a calpain activation inhibitor, muscle damage inhibitor, muscle endurance improver or muscle fatigue recovery agent containing an ω-methylsulfinylalkyl isothiocyanate or physiologically acceptable salt thereof as an active ingredient, foods or beverages, pharmaceuticals or cosmetics containing the same, a pharmaceutical for the prophylaxis and/or treatment of diseases related to muscle damage or diseases related to reduced muscle mass caused by aging, and a method for the use thereof. 153-. (canceled)54. A method comprising administering an effective amount of 6-methylsulfinylhexyl isothiocyanate or physiologically acceptable salt thereof to a subject.55. The method according to claim 54 , wherein the subject has muscle damage.56. The method according to claim 54 , wherein muscle damage is prevented in the subject.57. The method according to claim 54 , wherein the subject has one or more diseases and/or symptoms related to muscle damage caused by exercise loading.58. The method according to claim 54 , wherein one or more diseases and/or symptoms related to muscle damage caused by exercise loading are prevented in the subject.59. The method according to claim 54 , wherein the subject has muscular dystrophy or sarcopenia.60. The method according to claim 54 , wherein muscular dystrophy or sarcopenia is prevented in the subject. The present invention relates to a calpain activation inhibitor, muscle damage inhibitor, muscle endurance improver or muscle fatigue recovery agent containing an ω-methylsulfinylalkyl isothiocyanate or physiologically acceptable salt thereof as an active, foods or beverages, pharmaceuticals or cosmetics containing the same, a pharmaceutical for the prophylaxis and/or treatment of diseases related to muscle damage or diseases related to reduced muscle mass caused by aging, and a method for the use thereof.In response to a growing trend towards health consciousness in recent years, an increasing number of persons ...

Method for Treating Skin Cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 112-. (canceled)13. A method for treating skin cancer , with a lysine derivative surfactant having an isothiocyanate functional group , comprising the step(s) of:applying a lysine derivative surfactant to an area affected by skin cancer, wherein the lysine derivative surfactant comprises an alkanoyl substituent containing at least 8 carbon atoms bound to the α-nitrogen of the lysine, and further wherein the ε-nitrogen of the lysine forms part of an isothiocyanate functional group.14. The method for treating skin cancer according to claim 13 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma claim 13 , squamous cell carcinoma claim 13 , melanoma claim 13 , and merkel cell carcinoma.15. The method for treating skin cancer according to claim 13 , further comprising the step of applying an additional surfactant claim 13 , wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant claim 13 , an anionic surfactant claim 13 , a cationic surfactant claim 13 , a zwitterionic surfactant claim 13 , and combinations thereof.16. The method for treating skin cancer according to claim 13 , further comprising the step of applying an additional surfactant claim 13 , wherein the additional surfactant comprises a non-ionic surfactant.17. The method for treating skin cancer according to claim 16 , wherein the non-ionic surfactant is selected from at least one of the group comprising alcohols claim 16 , alkanolamides claim 16 , amine oxides claim 16 , esters claim 16 , glycerides claim 16 , ethoxylated glycerides claim 16 , polyglyceryl esters claim 16 ...

Method for Evaluating or Selecting Agent for Reducing Sensory Irritation

To provide a method for evaluating or selecting an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens, and an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens. A method for evaluating or selecting an agent for reducing sensory irritation caused by parabens, comprising the following steps (1) to (3): (1) a step of contacting cells capable of expressing CES1 with a test substance; (2) a step of measuring expression of CES1 in the cells; (3) a step of evaluating a test substance which promotes expression of CES1 as an agent for reducing sensory irritation caused by parabens based on the results measured in (2).

COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS

This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention.

METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA (BPH), PROSTATITIS, AND PROSTATE CANCER

A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 1. A method for treating benign prostatic hyperplasia (BPH) , prostatitis , and/or prostate cancer , comprising the step of:administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.2. The method for treating benign prostatic hyperplasia claim 1 , prostatitis claim 1 , and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.3. The method for treating benign prostatic hyperplasia claim 1 , prostatitis claim 1 , and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant comprises a lysine derivative claim 1 , wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen claim 1 , and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen claim 1 , and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.12. The method for treating benign prostatic hyperplasia claim 1 , prostatitis claim 1 , and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally claim 1 , intravenously claim 1 , intramuscularly claim 1 , intrathecally claim 1 , cutaneously claim 1 , subcutaneously claim 1 , transdermally claim 1 , sublingually claim 1 , buccally claim 1 , ...

INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 1. A method for reducing macrophage migration inhibitory factor cytokine or its biological activity , comprising the step of:administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.2. The method according to claim 1 , wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.3. The method according to claim 1 , wherein the isothiocyanate functional surfactant comprises a lysine derivative claim 1 , wherein the lysine derivative comprises an α-nitrogen and a 6-nitrogen claim 1 , and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen claim 1 , and further wherein at least one isothiocyanate functional group is associated with the 6-nitrogen.12. The method according to claim 1 , wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally claim 1 , intravenously claim 1 , intramuscularly claim 1 , intrathecally claim 1 , cutaneously claim 1 , subcutaneously claim 1 , transdermally claim 1 , sublingually claim 1 , buccally claim 1 , rectally claim 1 , vaginally claim 1 , ocularly claim 1 , otically claim 1 , and nasally.13. The method according to claim 12 , wherein the amount of isothiocyanate functional surfactant topically ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 164-. (canceled) The invention relates to the use of phenylalkylamine compounds which block L-type calcium channels to treat cardiovascular disorders.Calcium channel blockers (CCBs) are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias and include a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. Calcium influx through these channels initiates a process of electromechanical coupling that ultimately leads to muscle contraction. The ability to regulate the entry of calcium into cardiac and vascular smooth muscle cells is a powerful therapeutic approach to the treatment of angina and hypertension, respectively. Likewise, blocking calcium influx into cardiac tissues and conduction systems provides a useful approach to control certain types of arrhythmia.Serum esterases play an important role in the hydrolytic biotransformation of a vast number of structurally diverse drugs. These enzymes are major determinants of the pharmacokinetic behavior of most therapeutic agents containing ester bonds. Serum esterases are classified into three groups, A-, B-, and C-esterases, based on their interaction with organophosphates (De Vriese et al., Endocrinology (2004) 145, No. 11, 4997-5005). A-esterases, including arylesterase/paraoxonase, ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 164-. (canceled) The invention relates to the use of phenylalkylamine compounds which block L-type calcium channels to treat cardiovascular disorders.Calcium Channel BlockersCalcium channel blockers (CCBs) are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias and include a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. Calcium influx through these channels initiates a process of electromechanical coupling that ultimately leads to muscle contraction. The ability to regulate the entry of calcium into cardiac and vascular smooth muscle cells is a powerful therapeutic approach to the treatment of angina and hypertension, respectively. Likewise, blocking calcium influx into cardiac tissues and conduction systems provides a useful approach to control certain types of arrhythmia.Serum EsterasesSerum esterases play an important role in the hydrolytic biotransformation of a vast number of structurally diverse drugs. These enzymes are major determinants of the pharmacokinetic behavior of most therapeutic agents containing ester bonds. Serum esterases are classified into three groups, A-, B-, and C-esterases, based on their interaction with organophosphates (De Vriese et al., Endocrinology (2004) 145, No. 11, 4997-5005). A- ...

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. 164-. (canceled) The invention relates to the use of phenylalkylamine compounds which block L-type calcium channels to treat cardiovascular disorders.Calcium channel blockers (CCBs) are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias and include a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. Calcium influx through these channels initiates a process of electromechanical coupling that ultimately leads to muscle contraction. The ability to regulate the entry of calcium into cardiac and vascular smooth muscle cells is a powerful therapeutic approach to the treatment of angina and hypertension, respectively. Likewise, blocking calcium influx into cardiac tissues and conduction systems provides a useful approach to control certain types of arrhythmia.Serum esterases play an important role in the hydrolytic biotransformation of a vast number of structurally diverse drugs. These enzymes are major determinants of the pharmacokinetic behavior of most therapeutic agents containing ester bonds. Serum esterases are classified into three groups, A-, B-, and C-esterases, based on their interaction with organophosphates (De Vriese et al., Endocrinology (2004) 145, No. 11, 4997-5005). A-esterases, including arylesterase/paraoxonase, ...

METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 1. A method for treating an infectious disease , comprising the step of:administering an isothiocyanate functional surfactant to a patient having an infectious disease.2. The method according to claim 1 , wherein the infectious disease comprises at least one of a bacterial infection claim 1 , a fungal infection claim 1 , a prion infection claim 1 , a protozoan infection claim 1 , and a viral infection.3chlamydiastaphylococcus aureuspseudotuberculosissalmonellosisstaphylococcus. The method according to claim 2 , wherein the bacterial infection comprises at least one of actinomycosis claim 2 , anthrax claim 2 , bejel claim 2 , boutonneuse fever claim 2 , brucellosis claim 2 , brucellosis spondylitis claim 2 , bubonic plague claim 2 , campylobacteriosis claim 2 , carrion disease claim 2 , cat scratch disease claim 2 , cervicitis claim 2 , chancroid claim 2 , claim 2 , lymphogranuloma venereum claim 2 , cholera claim 2 , clostridial infection claim 2 , dysentery claim 2 , shigellosis claim 2 , epididymitis claim 2 , erysipelothrix infection claim 2 , glanders claim 2 , gonorrhea claim 2 , granuloma inguinale claim 2 , gumma claim 2 , legionnaire disease claim 2 , leprosy claim 2 , leptospirosis claim 2 , listeriosis claim 2 , lyme disease claim 2 , melioidosis claim 2 , methicillin-resistant claim 2 , nocardiosis claim 2 , paratyphoid fever claim 2 , pharyngitis claim 2 , plague claim 2 , pneumonia claim 2 , proctitis claim 2 , claim 2 , psittacosis claim 2 , q-fever claim 2 , rat-bite fever claim 2 , Reiter syndrome claim 2 , relapsing fever claim 2 , rheumatic fever claim 2 , Rocky Mountain spotted fever claim 2 , claim 2 , scarlet fever claim 2 , scrofula claim 2 , scrub ...

Pharmaceutical Composition Having Synergistic Action Of Direct Catalase Inhibitors And Modulators Of NO Metabolism Or Of Extracellular Superoxide Anion Production Which Lead To Catalase Destruction

The present patent application relates to a pharmaceutical composition, characterized in that it comprises at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and that the composition further comprises at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation. 1. A pharmaceutical composition comprising (a) at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and (b) at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation.2. The pharmaceutical composition according to claim 1 , wherein the at least one active ingredient (a) that is capable of singlet oxygen-independent direct inactivation of the catalase comprises an antibody against superoxide dismutase.3. The pharmaceutical composition according to claim 1 , wherein the at least one active ingredient (a) that is capable of singlet oxygen-independent direct inactivation of the catalase is selected from group consisting of antibodies against catalase claim 1 , salicylic acid claim 1 , ascorbic acid claim 1 , and methyldopa.4. The pharmaceutical composition according to claim 1 , wherein the at least one active ingredient (b) that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation comprises a substance that can increase the available nitrogen oxide concentration in cells.5. The pharmaceutical composition according to claim 4 , wherein the at least one active ingredient (b) that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and ...

Compositions and Methods for Treating Autism Spectrum Disorders

The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivative thereof) or (2) a glucosinolate, and optionally, an enzyme, to thereby treat an autism spectrum disorder and/or reduce the severity of at least one symptom of the disorder. Methods for preparing such compositions are also featured. 1. A method for treating an autism spectrum disorder in a human , the method comprising administering to the human daily a composition comprising an effective amount of an isothiocyanate , to thereby treat the disorder , wherein the effective amount is: between 25 and 75 μmol if the human weighs 100 pounds or less; between 75 and 125 μmol if the human weighs between 101 to 199 pounds; or between 125 and 175 μmol if the human weighs more than 200 pounds.2. The method of claim 1 , wherein the amount is 50 μmol claim 1 , if the human weighs 100 pounds or less; 100 μmol if the human weighs between 101-199 pounds; or 150 μmol if the human weighs more than 200 pounds.3. The method of claim 1 , wherein the amount is administered daily as one dose.4. The method of claim 1 , wherein the amount is administered daily as more than one dose.5. The method of claim 1 , wherein the isothiocyanate is administered to the human for at least 18 weeks.6. The method of claim 1 , wherein the disorder is autism.7. The method of claim 6 , wherein the human has moderate to severe autism.8. The method of claim 1 , wherein the amount is effective to reduce the severity of one or more behavioral symptoms of the disorder.9. The method of claim 1 , wherein the human has a medical history of behavioral improvements with fever.10. The method of claim 1 , wherein the isothiocyanate is sulforaphane or a derivative thereof.11. The method of claim 10 , wherein the sulforaphane is enantiopure for the (R) enantiomer.12. The method of claim 1 ...

COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2

Described herein are compositions and methods for treating Alzheimer's disease or dementia. The compositions include mammalian suppressor of taupathy 2 inhibitors (MSUT2). The MSUT2 inhibitors can be small interfering RNAs, guide RNAs, or small molecules. The methods include reducing accumulation of phosphorylated and aggregated human tau.

METHODS AND ASSAYS RELATING TO RNF216

The technology described herein relates to the diagnosis and treatment of Gordon Holmes Syndrome and cortical degradation. 134.-. (canceled)35. A method of treating a reproductive or sex hormone-dependent condition in a subject in need thereof , the method comprising administering to the subject a proteasome agonist selected from the group consisting of:SFN (1-isothio-cyanato-4(R)-methylsulfinylbutane); (methylsulfonyl)cyclohexylmethylisothiocyanante; oleuropein; betulinic acid; and derivatives thereof.36. The method of claim 35 , wherein the reproductive disease is selected from the group consisting of:hypogonadotropic hypogonadism; delayed puberty; amenorrhea; irregular menstrual function; polycystic ovary syndrome; erectile dysfunction; decreased libido; azoospermia; and infertility.37. A method of treating a subject claim 35 , the method comprising:detecting, in a sample obtained from a subject, the presence of a deleterious mutation in RNF216 and optionally, OTUD4; andadministering a treatment for Gordon Holmes syndrome to the subject.38. The method of claim 37 , wherein the treatment increases the expression or activity of RNF216 and optionally claim 37 , OTUD4.39. The method of claim 37 , wherein the treatment is selected from the group consisting of:an ubiquitin acting drug; a drug acting within the proteasome; a drug acting within the ataxia protein protein interaction network; a USP14 inhibitor; IU1; calcium channel blockers; pioglitazone; conenzyme Q10; idebenone; overexpression of heat shock proteins; inhibitors of ATXN1; zolpidem; varenicline; implantation of syngenic cerebellar, gonadotroph, or hypothalaus cells; and implantation of genetically-modified cerebellar, gonadotroph, or hypothalaus cells.40. The method of claim 39 , wherein the drug acting within the proteasome is a proteasome agonist selected from the group consisting of:SFN (1-isothio-cyanato-4(R)-methylsulfinylbutane); (methylsulfonyl)cyclohexylmethylisothiocyanante; oleuropein; betulinic ...

Treatment for Skeletal Diseases Caused by Intracellular Protein Trafficking Defects

The present invention includes a method of treating a bone disease caused by a intracellular protein trafficking defect comprising: identifying a subject having the bone disease caused by the intracellular protein trafficking defect in a membrane bound transcription factor peptidase, site 1 (MBTPS1) gene; and providing the subject with an effective amount of a composition that bypasses or corrects a defect in MBTPS1 gene expression, gene splicing, or corrects protein trafficking defects in the endoplasmic reticulum and to the lysosome. 1. A method of treating a bone disease caused by an intracellular protein trafficking defect comprising:identifying a subject having the bone disease caused by the intracellular protein trafficking defect in a membrane bound transcription factor peptidase, site 1 (MBTPS1) gene; andproviding the subject with an effective amount of a composition that bypasses or corrects a defect in MBTPS1 gene expression, gene splicing, or corrects lysosomal protein trafficking.2. The method of claim 1 , wherein the composition comprises an expression vector that expresses at least one of MBTPS1 gene claim 1 , a BBF2 human homolog on chromosome 7 (BBF2H7) transcription factor claim 1 , a constitutively active form of BBF2H7 (p60) Sec23a claim 1 , Tango1 claim 1 , Sedlin claim 1 , Hsp47 claim 1 , or an endoplasmic reticulum ER chaperone corrects a defect in a mutant MBTP S1 protein.36.-. (canceled)7. The method of claim 1 , wherein the composition induces immunoglobulin heavy-chain binding protein (BiP) expression selected from 1-(3 claim 1 ,4-dihydroxy-phenyl)-2-thiocyanate-ethanone r is a composition that improves osteogenicity from mesenchymal stem cells (MSCs) differentiated from iPSCs obtained from the subject.89.-. (canceled)10. The method of claim 1 , wherein the composition comprises a chemical chaperone selected from phenylbutyrate (4-PBA) claim 1 , glycerol phenyl butyrate claim 1 , sodium phenylbutyrate claim 1 , phenylbutyrate salts claim 1 ...

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER BY TARGETING AND INHIBITING CANCER STEM CELLS

The invention includes compositions and methods for treating cancer comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, methods of inhibiting the growth of cancer stem cells or tumor initiating cell comprising administering to a subject in need a pharmaceutically effective amount of a pharmaceutical composition for inhibiting cancer stem cells. The pharmaceutical composition includes various combinations of sulforaphane, resveratrol, mangostine, honokiol, diallyltrisulphide and gemcitabine. 1. A method of treating or preventing a cancer by targeting and inhibiting cancer stem cells , comprising administering to a subject in need thereof a pharmaceutically effective amount of a pharmaceutical composition and a vehicle for inhibiting the cancer stem cells.2. The method of treating or preventing a cancer by targeting and inhibiting cancer stem cells as claimed in claim 1 , wherein the pharmaceutical composition comprises sulforaphane claim 1 , resveratrol claim 1 , mangostine claim 1 , honokiol and diallyltrisulphide.3. The method of treating or preventing a cancer by targeting and inhibiting cancer stem cells as claimed in claim 1 , wherein the pharmaceutical composition comprises sulphoraphane claim 1 , resveratrol and gemcitabine.4. The method of treating or preventing a cancer by targeting and inhibiting cancer stem cells as claimed in claim 1 , wherein the pharmaceutical composition comprises mangostine claim 1 , resveratrol and gemcitabine.5. The method of treating or preventing a cancer by targeting and inhibiting cancer stem cells as claimed in claim 1 , wherein the pharmaceutical composition comprises honokiol claim 1 , resveratrol and gemcitabine.6. The method of treating or preventing a cancer by targeting and inhibiting cancer stem cells as claimed in claim 1 , wherein the vehicle is selected from the group consisting of liposomes claim 1 , micelles claim 1 , polymers claim 1 , dendrimers claim 1 ...